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ABSTRACT 
Chronic pain in autoimmune diseases, like rheumatoid arthritis (RA), is a common and life-
changing problem for many patients. Treatment is usually aimed at reducing inflammation 
and preserving the function of affected tissues. Chronic pain, however, often persists despite 
optimal disease control. Autoimmune pain arises from multiple mechanisms with a wide 
range of characteristics that differs between individuals. For effective management of the 
pain, it is essential to understand these mechanisms. 
One of the hallmarks in the pathogenesis in most autoimmune diseases is the presence of 
autoantibodies. In RA, several types of antibodies are well characterized, but little is known 
about their interaction with the sensory system. Thus, the aim of this thesis is explore 
mechanisms involved in pain signaling, specifically the role of disease-relevant antibodies as 
inducers of pain. 
In Paper I and II, we investigate the effect of anti-citrullinated protein antibodies (ACPA) on 
pain behavior and interaction with immune cells. When injected into mice, both polyclonal 
human ACPA or murinized monoclonal ACPA induces spontaneous and evoked pain-like 
behavior in the absence of inflammation. Additionally, the antibodies induce trabecular bone 
loss measured with micro-CT. The antibodies localize to joint and bone marrow, binding 
osteoclasts and its precursors. Using cultures of mice and human osteoclasts, we show that 
ACPA bind structures on the cells, causing proliferation and release of the chemokine 
CXCL1/IL-8. The effect of the release is increased bone resorption and activation of sensory 
neurons, causing pain-like behavior, which can be reversed by treating the mice with the 
CXCR1/2 blocker reparixin. 
In Paper III, we demonstrate that mice injected with antibodies specific to the cartilage 
protein collagen type II (anti-CII mAbs) displays pronounced mechanical hypersensitivity 
and reduction in locomotion at time points when visual, histological and molecular 
indications of inflammation were completely absent. Further, this effect was not mediated by 
the activation of complement factors or by changes in the cartilage structure. Instead our data 
point to a direct action of anti-CII mAb/collagen immune complexes on the sensory neurons 
through neuronally expressed Fc-gamma receptor IIb (FcγRIIb), causing increased inward 
currents, intracellular Ca2+ levels, and calcitonin-gene related peptide (CGRP) release. 
Importantly, the nociceptive properties of anti-CII mAbs were lost when the Fc-FcγR 
interaction was disrupted in vivo. 
In summary, we have described two novel mechanisms of how disease-relevant antibodies 
can activate sensory neurons, causing pain-like behavior. These results deepen the 
understanding of pain mechanisms in autoimmune disease and potentially to new ways of 
treating the pain component in patients. 
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1 INTRODUCTION 
Chronic pain is a major health problem affecting a large portion of the population, causing a 
marked reduction in the quality of life for the individual as well as large socioeconomic costs. 
It has been estimated that chronic pain conditions are the major contributor to Years lived 
with disability (YLD) globally(Vos et al., 2012), where pain due to muscoskeletal joint 
disorders like osteoarthritis (OA) and rheumatoid arthritis (RA) are common causes (Breivik 
et al., 2006; Vos et al., 2012). RA is a systemic autoimmune disease that affects around 1% 
of the population. Recent enhanced understanding of the molecular pathogenesis has greatly 
improved treatment outcomes (Firestein, 2003; McInnes and Schett, 2007), but many 
patients still suffer from joint pain (Altawil et al., 2016; Lee et al., 2011). Pharmacological 
treatments of pain are often associated with side effects and lack of efficacy, making pain 
management clinically challenging (Walsh and McWilliams, 2014). Therefore it is critical to 
increase our understanding of the mechanisms establishing chronic pain so that we can 
identify novel targets and treatment strategies for more effective pain relief. 
 
1.1 RHEUMATOID ARTHRITIS 
RA is a systemic autoimmune disease where the autoreactivity primarily affects the joints, 
causing pain and swelling. Pain and stiffness is often increased in the morning and after 
periods of rest. The course of the disease varies greatly, some patients have mild short-term 
symptoms but most have progressive life-long symptoms. RA is present in all human 
populations with some regional differences, with the highest prevalence in Western Europe, 
affecting women approximately three times more than men (Cross et al., 2014; Firestein, 
2003; Klareskog et al., 2009; Scott et al., 2010). 
1.1.1 Criteria 
Arthritis means inflammation in the joints and is a symptom of many different diseases, 
including osteoarthritis, psoriatic arthritis, and gout. In order to study RA in a meaningful 
way it is important to cluster patients and to have uniform criteria for the definition of the 
disease. The most recent classification criteria for RA were delineated in 2010 by ACR and 
EULAR (Aletaha et al., 2010) (see Table 1). Patients that are scored need to satisfy two 
criteria: 1) have at least 1 joint with definite clinical synovitis that 2) cannot be better 
explained by another disease. A score of 6 out of maximum 10 is defined as having RA. 
Points are given for number of joints involved and presence of autoantibodies, anti-
citrullinated protein antibodies (ACPA) or rheumatoid factor (RF) are given more weight in 
the scoring. The term seropositive refers to presence of either ACPA or RF, this does not 
exclude seronegative patients from having other types of autoantibodies. Importantly, in the 
definition for “involvement”, tenderness or pain is included as an equal important feature as 
swelling, indicating that the sensory component is an integral part of the disease process. It is 
important to note that RA is a very heterogeneous disease or syndrome with several patient 
 2 
subsets that presents with similar symptoms, i.e. inflammation in the joints. This is true also 
in animal studies where arthritis-like symptoms can be triggered in a number of ways. 
Different molecular pathways and processes are likely to be activated in different patients 
(Klareskog et al., 2013b), contributing to the heterogeneity. 
 
Table 1 The 2010 ACR/EULAR classification criteria for RA 
Criteria Manifestations Score 
A. Joint involvement 
1 large joint 
2-4 large joints 
1-3 small joints 
4-10 small joints 
>10 joints (at least one small joint) 
0 
1 
2 
3 
5 
B. Serology 
Negative RF and negative ACPA 
Low-positive RF or low-positive ACPA 
High-positive RF or high-positive ACPA 
0 
2 
3 
C. Acute-phase reactants 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR 
0 
1 
D. Duration of symptoms 
<6 weeks 
≥6 weeks 
0 
1 
Total score of at least 6 out of 10 is defined as RA. Involved joint means swelling or tenderness. Large joint 
refers to shoulders, elbows, hips, knees, and ankles. Small joint refers to MCP, PIP, second to fifth MTP, thumb 
interphalangeal joints and the wrist. 
 
1.1.2 Etiology 
The cause of RA is not clear but several risk factors have been identified. It is a complex 
genetic disease, meaning that it involves several genes, environmental triggers and chance. In 
twin studies, the genetic risk have been estimated to 50% (MacGregor et al., 2000). The 
genes that are strongly associated in disease are often involved in the function of the immune 
system, especially T cell activation and the NF-κB pathway (McInnes and Schett, 2011). 
Seropositive RA is especially associated with a conserved amino acid motif in the HLA-
DRB1 region called shared epitope (SE) (Gregersen et al., 1987), suggesting that 
predisposing T cell selection, antigen presentation or peptide affinity has a role in formation 
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of pathogenic autoantibodies. It is still not known where or how the disease is initiated but 
important information can come from environmental risk factors. Several factors have been 
implicated, like periodontitis (Mercado et al., 2000)and particular strains of gut microbiota 
(Scher et al., 2013), but the strongest evidence is linked to the lungs, involving cigarette 
smoking (Symmons et al., 1997) and other airway exposures (Klockars et al., 1987). 
Recently a strong risk interaction was found between HLA-DR and smoking in seropositive 
patients, linking genes and environment (Klareskog et al., 2006). This suggests that 
seropositive patients have a fundamentally different disease from seronegative patients. 
1.1.3 Disease course 
1.1.3.1 “Pre-RA” 
Rheumatoid arthritis is a disease that develops over time, with several events taking place 
before the onset of symptoms and subsequent diagnosis. This phase is often referred to as 
“pre-articular” or “pre-RA”. Studies have shown the presence of several types of 
autoantibodies up to 10 years before the onset of disease (Kurki et al., 1992; Nielen et al., 
2004; Rantapää-Dahlqvist et al., 2003), with increasing titers and epitope spreading over 
time. Interestingly, this phase is associated with little to no detectable inflammation but 
with arthralgia as an early symptom (de Hair et al., 2014; van Baarsen et al., 2013). This 
means that the initial formation of autoimmunity is a very early event that most likely is 
triggered outside the joint (Klareskog et al., 2013a), that can transition to arthralgia and 
autoimmune disease involving the joints. Little is know of the molecular mechanisms 
behind these transitions since most genetic and environmental studies are performed on 
established RA populations (Catrina et al., 2016; 2014; Klareskog et al., 2013a). Increased 
understanding of the events leading up to diagnosis would provide opportunities for 
interventions that could efficiently reduce symptoms and potentially inhibit progression. 
1.1.3.2 Established RA 
In RA the pathogenic autoreactivity primarily targets structures in the joints and is 
characterized by the presence of several types of autoantibodies that are used both for 
diagnosis and sub-categorization of patients. The autoantibodies bind epitopes in the 
synovia causing recruitment and activation of lymphocytes, monocytes and fibroblasts. In 
early rheumatoid arthritis, the small joints in hands and feet are predominantly targeted but 
as the disease progresses also larger joints such as the wrists, knees, ankles and hips are 
also affected, leading to pain, inflammation and hyperplasia of the synovia, cartilage and 
bone destruction (Fig. 1). The presence of pannus, an aggressive invasive front of various 
cells, eventually invades and destroys local surrounding tissues, causing loss of joint 
function (Firestein, 2003; McInnes and Schett, 2011). About 40% of patients present with 
extra-articular systemic effects like cardiovascular illness, pulmonary disorders, and 
reduced cognitive function, likely due circulating cytokines and immune complexes (ICs) 
(McInnes and Schett, 2011). Established RA is often polycyclic, with fluctuating disease 
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activity over time, but can also be monocyclic, with one episode that ends within a couple 
of years after diagnosis. Other patients have a progressive RA that continues to increase in 
severity over time (Graudal et al., 1998; Masi et al., 1976; Pincus and Callahan, 1993). 
 
Figure 1. The normal joint and 
changes in RA. The synovial joint 
is composed of two adjacent bone 
ends in apposition, each covered 
with a layer of cartilage separated 
by a joint space that contains the 
synovial fluid (a). The arthritic 
joint is characterized synovitis, 
influx and local activation of a 
variety of immune cells. The 
synovia becomes hyperplastic, 
cartilage becomes eroded, and 
pannus infiltrates the bone. 
Destruction often starts at the 
cartilage-bone-synovial membrane 
junction (b). Modified from 
(Smolen and Steiner, 2003). 
 
1.1.4 Antibodies in RA 
Autoimmune diseases are associated with loss of immunological tolerance, which is the 
ability of the immune system to separate “self” from “non-self”. Lymphocytes are made to 
react with an enormous variety of antigens, some of which will be self-structures. 
Historically, the general idea was that all autoreactive B and T cells that reacted with self-
structures were deleted leaving only cells that were specific for foreign antigens. The present 
view is that a low level of autoreactivity is necessary for normal immune function (Dighiero 
and Rose, 1999), crucial for maintaining populations of lymphocytes in the periphery. It is 
speculated that lymphocytes have evolved to respond to antigens only in the presence of 
certain microenvironments, containing inflammatory cytokines (Silverstein and Rose, 2000). 
This means that development of autoimmune disease is not only dependent on dysfunction of 
immunological tolerance, but require several events after the formation of autoreactive 
immune cells. 
High titers of circulating autoantibodies is common in many autoimmune diseases and is 
often used as a diagnostic criteria (see Table 1) but their direct involvement in pathogenesis is 
not always clear. However, in RA the importance of antibodies and B cells in pathogenesis is 
supported not only from the original finding of rheumatoid factors (RF) (Franklin et al., 
1957), and its pathogenic potential (Sutton et al., 2000), but also from the observation that 
arthritis is mediated in experimental animals via B cells and by passive transfer of antibodies 
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(Stuart and Dixon, 1983; L. Svensson et al., 1998). Patients display a wide variety of 
antibody specificities and the antibody profile may sometimes predict disease progression and 
treatment response, for example seropositive RA has a worse prognosis than seronegative RA 
(van der Helm-van Mil et al., 2005). Researchers further improve the existing predictive 
models by integrating the antibody specificities with the known genetic and environmental 
risk factors. 
The model of RA as an autoimmune disease caused by antibodies dictates that antibodies 
bind epitopes in and around the joint causing formation of immune complexes (ICs) that 
drive the disease through activation of resident cells (macrophages, FLS) and complement 
fixation. This leads to subsequent release of chemotactic factors, which recruit immune cells 
(neutrophils, monocytes) to the joint. Both resident cells and infiltrating cells are activated by 
the ICs through Fc receptors (FcRs), which perpetuate the inflammatory process leading to 
tissue destruction (Firestein, 2003; Nandakumar and Holmdahl, 2006). Knowledge about the 
direct pathogenic potential of individual antibodies comes from animal studies and will be 
discussed more in section 1.3.  
1.1.4.1 Antibodies against native proteins 
Rheumatoid factor is defined as an antibody that binds the Fragment crystallizable (Fc) 
portion of another antibody (IgG). RF and IgG form large ICs thought to contribute to 
pathogenesis. RF is not specific for RA as it is detected in other autoimmune diseases, 
systemic infections, and up to 10% of healthy individuals (Carson et al., 1981; Franklin et 
al., 1957; Nell et al., 2005; Sutton et al., 2000), showing that additional events are necessary 
to establish pathogenic autoimmunity. The mechanism behind the relatively common 
occurrence of RF in autoimmune disease is likely to include a positive selection for B cells 
recognizing Fc-rich ICs (Davidson and Diamond, 2001; Roosnek and Lanzavecchia, 1991). 
Pathogenic RF undergoes affinity maturation and somatic hypermutation, suggesting that T 
cells are involved in the process (Bugatti et al., 2007).  
Glucose-6-phosphate isomerase (GPI) is a glycolytic enzyme in the cytoplasm of all cells. 
The articular cavity is lined with extracellular GPI for unknown reasons, and antibodies 
against GPI cause arthritis in mice (Ji et al., 2002; Matsumoto et al., 2002). Around 15% of 
RA patients have GPI antibodies, which is associated with higher disease activity 
(Matsumoto et al., 2003). Again, the occurrence of this antibody is not specific for RA, since 
other rheumatic diseases show similar prevalence. 
Collagen type II (CII) is the major protein in joint cartilage and anti-CII antibodies from 
patients can transfer arthritis to naïve mice (Wooley et al., 1984). Antibodies against collagen 
type II are commonly present in patients around onset of the disease (Cook et al., 1996; 
Holmdahl et al., 1993; Mullazehi et al., 2012). Reported prevalence in patient populations 
varies from a few percent up to 60% (Cook et al., 1996; Lindh et al., 2014; Mullazehi et al., 
2012), depending on type of assay and/or target epitopes used. The role of anti-CII immunity 
in initiating arthritis is well characterized in several species, targeting conserved epitopes on 
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the CII protein (Burkhardt et al., 2006; Lindh et al., 2014; Nandakumar and Holmdahl, 
2006). It is also one of the few common targets in RA with joint specificity, making these 
autoantibodies interesting for studying the effector phase in arthritis (Nandakumar and 
Holmdahl, 2006), which is described further below. In paper III, the role of anti-CII 
antibodies in inducing nociceptive signaling is studied. 
1.1.4.2 Antibodies against citrullinated proteins 
Citrullination is an example of post-translational modification (PTM) of proteins, which is a 
common occurrence and involves enzymatic modification of a protein after its biosynthesis 
(Fig. 2). New functional groups or molecules are formed or added, like phosphate, amide, 
carbohydrate, or lipid. This changes the functional properties of the protein and can 
activate/deactivate enzymes. Citrullination, also called deamination, is the conversion of the 
amino acid arginine (positive) to citrulline (neutral), which is performed by peptidyl arginine 
deiminases (PADs) (Vossenaar et al., 2003) in the presence of high concentrations of Ca2+. 
This changes the properties of the protein but the physiological function of this modification 
is incompletely understood. However, it seems that it renders the protein more immunogenic. 
PAD enzymes and citrullinated proteins have not been shown to be expressed in the thymus, 
so T cells with high affinity to citrullinated proteins would not be negatively selected and 
may enter peripheral tissues with citrulline specificity (Klareskog et al., 2013b). 
 
 
 
 
 
 
 
 
Figure 2. Representation of citrullination. Citrulline is formed by a post-translational calcium-dependent 
enzymatic reaction mediated by peptidylarginine deiminase (PAD). Modified from (Cerqueira et al., 2013). 
Antibodies against citrullinated proteins in RA were first demonstrated at the end of the 
1990s (Girbal-Neuhauser et al., 1999; Schellekens et al., 1998), which led to development of 
standardized assays for detection in patients and continued research. It became apparent that 
ACPA is present in 60-70% of RA patients and that it is highly specific for RA, the 
prevalence is very low in the general population and in other rheumatic conditions 
(Schellekens et al., 2000; van Gaalen et al., 2004). The targeted citrullinated epitopes are 
located on a variety of proteins, including fibrinogen, vimentin, CII, and a-enolase 
(Klareskog et al., 2013b), and recent studies show that the antibodies are inherently cross-
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reactive (Amara et al., 2013). An interesting feature of anti-citrulline immunity has come 
from studies using longitudinal serum samples from blood donors and patients. The 
occurrence of ACPA is seen several years before the onset of symptoms and diagnosis 
(Nielen et al., 2004; Rantapää-Dahlqvist et al., 2003). During this period the frequency of 
ACPA types, number of fine specificities, titers, and affinity remain low, until a period 6-12 
month before onset of clinical joint symptoms where the antibody characteristics change into 
high frequency, high number of specificities, high titer, and high affinity (Brink et al., 2013; 
Sokolove et al., 2012; Suwannalai et al., 2012; van de Stadt et al., 2011a). Importantly, 
arthralgia is often apparent in the patients before onset of other clinical symptoms (Bos et al., 
2010; van de Stadt et al., 2011b), suggesting that nociceptive signaling starts very early in 
the disease, in the pre-RA phase (Fig. 3). 
 
 
Figure 3. A three stage model for ACPA-positive RA. Stage 1, the immune response: Environmental risk 
factors, such as smoking, may induce citrullination of proteins in the lungs. Altered antigen uptake, processing, 
and presentation of citrullinated antigens could in genetically susceptible individuals (like HLA-DR SE positive) 
lead to production of ACPA. At this stage pain is apparent in many individuals. Stage 2, the pathological 
inflammatory response: Unspecific arthritis, accompanied by citrullination of proteins in the joints. Recruitment 
of ACPA from the circulation results in the formation of ICs. Stage 3, chronic RA: Generation of citrullinated 
proteins, influx of immune cells, and production of cytokines and autoantibodies, as a result of the immune 
complex formation, convert the joint inflammation into chronic RA. Adapted from (Klareskog et al., 2008). 
 
1.1.4.3 Effector mechanisms of antibodies 
Antibodies, also called immunoglobulins (Ig), are the major effector molecules of adaptive 
immunity. Antibodies can be grouped into five different isotypes; IgG, IgM, IgA, and IgE, 
which have different functions and distributions. The most common isotype in the circulation, 
both in normal condition and during disease, is IgG (75% of total Igs), and I am focusing on 
IgG in this thesis. The antigen-binding region (Fab) of the antibody is a hypervariable region 
 8 
capable of binding three-dimensional epitopes with high affinity (Fig. 4). The defense against 
microbes and modulation of immune function is done through a variety of mechanisms that 
always include binding of the Fab-region to the antigen. This can neutralize the function of 
toxins or viral particles, and help the body to clear the specific factor. Furthermore, the Fc-
part of the antibody activates the immune system, as macrophages and neutrophils will 
recognize antibodies bound to antigen and the target is eliminated by phagocytosis or 
antibody-dependent cellular cytotoxicity (ADCC) by NK cells. One or more antibodies 
bound to an antigen is called an immune complex (IC), and these creates a locally high 
concentration of antibodies, which augments the effector functions. The ICs can activate the 
complement cascade through the classical pathway, which involves Fc binding and cleavage 
of C1. These cleavage products initiate a cascade leading to lysis of target membranes (by 
membrane attack complex, MAC (C5b-C9)) and recruitment of immune cells (by C3a and 
C5a). 
Formation of ICs leads to a conformational change in the Fc part of the antibody, which 
enables it to associate with Fcγ receptors (FcγRs). Importantly, this binding is dependent on a 
glycan located at Asn297 on the Fc (Fig. 4). The presence of the glycan is a requirement for 
IgG activation of FcγR, as deglycosylation of IgG prevents the Fc-FcγR interaction (Anthony 
et al., 2012; Nandakumar et al., 2013). The Fc – FcγR interaction has low affinity but high 
avidity, meaning that complex formation is necessary for potent activation.  
 
Figure 4. Structure of IgG. The Y-
shaped structure of human IgG antibody. 
The heavy and light chains combine to 
form the two arms of the antigen-binding 
Fab portion, and the heavy chains extend 
to the Fc portion, which is responsible for 
initiating effector functions. The glycan 
attaches at Asn297 extends along the 
heavy chain backbone, inducing an open 
conformation of the Fc, able to interact 
with FcγR. Adapted from (Anthony et 
al., 2012). 
 
 
In mice there are four types FcγRs; FcγRI, FcγRIIb, FcγRIII and FcγRIV, with similar human 
orthologs (Fig. 5) FcγRs are coupled to intracellular tyrosine kinases and can be either 
activating or inhibitory depending on the motif. They are widely expressed on hematopoietic 
cells with some cell type specificity, monocytes and macrophages express all receptors while 
B cells only express the inhibitory FcγRIIb (Nimmerjahn and Ravetch, 2008). Activating 
FcγRI, III and IV have immunoreceptor tyrosine-based activation motifs (ITAM) that causes 
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the spleen tyrosine kinase (SYK) – phosphoinositide 3-kinase (PI3K) – phospholipase C 
(PLC) pathway to increase intracellular calcium levels and triggering of further downstream 
events (Odin et al., 1991). The inhibitory FcγRIIbs have immunoreceptor tyrosine-based 
inhibitory motifs (ITIM) and activation causes recruitment of phosphatases that leads to 
inhibition of PLC (Bolland and Ravetch, 1999), thus inhibiting ITAM-induced intracellular 
calcium increases. 
 
Figure 5. The family of Fc receptors for IgG. Human and mouse FcγRs can be distinguished by their affinity 
for the antibody Fc-fragment and by the signaling pathways they induce. Mice and humans have one high-
affinity receptor, FcγRI. All other FcRs have low to medium affinity. There is one single-chain inhibitory 
receptor, FcγRIIb, which contains an immunoreceptor tyrosine based inhibitory motif (ITIM) in its cytoplasmic 
domain. With the exception of human FcγRIIA and FcγRIIC, an activating FcR usually consists of a ligand-
binding α-chain and a signal transducing γ-chain dimer, which carry immunoreceptor tyrosine based activating 
motifs (ITAM). A variety of  human  FcγR alleles with altered functionality exists, for example FcγRIIA131H 
have higher affinity to certain IgG subclasses compared to their allelic counterparts. Adapted from (Nimmerjahn 
and Ravetch, 2008). 
 
Much of the information on FcγRs comes from studies of immune cells. However, several 
recent studies have shown expression and function of FcγRs in both central and peripheral 
neurons (Okun et al., 2010). Neuronal FcγRIIb is involved in cerebellar function and 
Alzheimer pathology of the hippocampus (Kam et al., 2013; Nakamura et al., 2007). In the 
periphery, motor neurons have been shown to take up ICs in their terminals, a process 
mediated by FcγRs that causes increases in intracellular calcium (Mohamed et al., 2002). The 
first evidence relating to sensory neurons came from in vitro studies using dissociated mouse 
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DRGs, which showed that IC triggering increased calcium and release of substance P (Andoh 
and Kuraishi, 2004). This was later repeated in cultures from rats, implicating TRPC3 as a 
key molecular target for the excitatory effect (Qu et al., 2012; 2011). So far, no studies have 
explored the contribution of FcγR to in vivo pain-behavior, which is the focus of Paper III. 
 
1.2 PAIN IN RA 
The primary goal of the treatment of patients with RA is to maximize long-term, health-
related quality of life through control of symptoms, prevention of structural damage, and 
normalization of function and social participation (Smolen et al., 2010). Thus, reducing pain 
is one of the most important aims of therapy. Additionally, RA patients often rate pain as one 
of their most significant problems (da Silva et al., 2010; Heiberg and Kvien, 2002). 
Unfortunately, chronic pain in patients with RA remains a major clinical problem, even when 
the disease is under control or even in remission (Lee et al., 2011; Welsing et al., 2005). The 
pain reported varies between individuals and can occur upon mechanical stimulation of the 
joint, during movement, or spontaneously while at rest. When asked to describe the pain, 
patients with active disease often use words like shooting, throbbing, and sharp, while less-
active disease is often is described as tender, dullness, and gnawing (Burckhardt, 1984; 
Roche et al., 2003). Interestingly, many RA patients also report pain characteristics that are 
associated with neuropathic (nerve-injury) pain, like burning pain on touch and sudden 
electric shock-like attacks (Harden, 2005). This suggests that the nature of pain in RA is 
more complex than that solely due to inflammation. In fact, there is poor correlation between 
disease activity and pain (Altawil et al., 2016; Koop et al., 2015). 
1.2.1 The nociceptive system 
Primary sensory neurons relay information about our internal and external environments from 
tissues to the brain, through the spinal cord or trigeminal system, allowing us to perceive 
noxious and non-noxious stimuli (Fig. 6). Pain, per definition, is an unpleasant sensory and 
emotional experience, which is often dependent on nociceptive input from the periphery. The 
sensory neurons have highly specialized adaptations to respond to a variety of mechanical, 
thermal, and chemical inputs. The heterogeneity in responses is mediated by differences in 
restricted localization, and expression of receptors, neuropeptides, and ion channels.  
It is important to note the difference between acute and chronic pain. Acute tissue insults 
such as heat, cold, chemical or mechanical injury stimulate the nociceptors (pain receptors), 
located at the endings of the nociceptive primary neurons. The ability to detect and rapidly 
respond to noxious stimuli is vital for the survival of any organism. Pain causes advantageous 
behavioral changes, such as withdrawal of a limb from a flame or by reducing the use of a 
broken foot (Fig. 6). The modified behavior will prevent tissue damage or allow healing. 
Withdrawal from the acute stimulus and full tissue recovery should result in restoration of 
homeostasis and end the activity in the pain pathways. However, continuous or repetitive 
nociceptive stimulation can lead to a series of pathophysiological changes in pain 
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processing such that the pain signaling outlives its usefulness as a warning system, and the 
pain becomes chronic and debilitating. This shift from acute to chronic pain is mediated via 
complex changes initiated and maintained at both peripheral and central locations. This 
implicates that pain is not generated by a static, hardwired system, but instead results from 
the summation effect of highly plastic mechanisms and circuits. 
 
 
Figure 6. Nociceptive pathway and 
withdrawal reflex. Noxious stimuli are 
sensed by nociceptors that signal to the 
spinal cord, where the afferents synapse 
with projection neurons that send signals 
to the brain where the pain is perceived. 
Additional synapse is made from the 
primary afferent to interneurons, which 
activate flexor motor neurons to elicit 
withdrawal of the affected limb. Adapted 
from (Talbot et al., 2016). 
 
 
 
 
 
1.2.1.1 Nociceptor classification 
Nociceptor are peripheral sensory nerve fibers that detect noxious stimuli, suggesting 
molecular or biophysical properties to selectively respond to potentially damaging stimuli. 
Their cell bodies are located in the dorsal root ganglia (DRG) for the body and trigeminal 
ganglion (TG) for the face, and have branches innervating both the target organ and the 
dorsal horn of the spinal cord or the spinal nucleus of the trigeminal complex. Nociceptors 
are very heterogeneous and can be broadly classified according to fiber diameter and degree 
of myelination, which determines conduction speed. Generally, medium diameter myelinated 
afferents (Aδ) mediate fast, localized pain, while small diameter, unmyelinated C-fibers 
signal poorly localized, slow pain. The large diameter myelinated fibers (Aβ) are often 
associated with fast conducting low-threshold mechanoreceptors, but a substantial proportion 
of A-fiber nociceptors are Aβ-type (Djouhri and Lawson, 2004; Schaible et al., 2009). Aδ 
and C-fibers can be further subdivided into sub-classes. Type I Aδ include high threshold 
mechanical (HTM) nociceptors that respond to both mechanical, chemical stimuli but with a 
high heat threshold (above 50°C). Type II Aδ nociceptors have a lower heat threshold but a 
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much higher mechanical threshold. The C-fibers are highly heterogenous and most are 
polymodal (Fig. 7), often referred to as heat and mechanically sensitive, while other respond 
to mechano-cold or just heat. One population of unyelinated C-fibers, common in joints, are 
called “silent nociceptors” as they are unresponsive to mechanical stimulation during normal 
conditions but become responsive after e.g. an injury, and likely contribute largely to both 
initiation and maintenance of hypersensitive states(Basbaum et al., 2009; Schaible and 
Schmidt, 1985). Glutamate is the primary neurotransmittor for all nociceptors, while 
subtypes of C-fibers also synthesise peptides like substance P and calcitonin gene-related 
peptide (CGRP). These peptidergic fibers often express the NGF-receptor TrkA. The 
nonpeptidergic C-fibers express the IB4 isolectin, as well as purinergic receptors of the P2X 
types (Basbaum et al., 2009). The variety of nociceptor functional and molecular subclasses 
associate with specific detection of pain modalities. 
1.2.1.2 Signal initiation and transduction 
The primary efferent nerve terminal detects environmental stimuli, converts them into 
changes in membrane potential and summates them. If the resulting generator potential, or 
depolarization, is sufficient, it is transformed into action potentials and the signal is 
propagated along the nerve to the dorsal horn. The detection in the terminal is done in 
different ways depending on the receptor type, which determines if the fiber is nociceptive or 
not. Sensory neurons express at least three classes of surface proteins that affect signal 
initiation and transduction: ion channels, metabotropic G protein-coupled receptors (GPCRs), 
and receptors for neurotrophins and cytokines (Fig. 7). 
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Figure 7. Heterogeneity of nociceptors. One way of classifying nociceptors is by the response profile of the 
afferent. Illustration of a sensory nerve with peripheral terminal to the left and central terminal to the right. 
Example of a polymodal afferent that responds to mechanical, thermal and chemical stimuli, due to various 
receptors on the same afferent. Voltage-gated channels along the nerve propagate the signal to the central 
terminal in the dorsal horn, where several ion channels and receptors modify transmittor release. Adapted from 
(Gold and Gebhart, 2010). 
Nociceptors express a wide variety of ligand gated ion channels that responds to stimuli and 
can rapidly change the membrane potential. One of the most studied class is the TRP 
channels, which have a high permeability to calcium and are multimodal receptors (Julius, 
2013). TRPV1 defines a population of nerve fibers that are activated by noxious heat ( above 
43°C), low pH (5.2), capsaicin, and certain lipids. TRPM8 is in the same receptor class but 
detects innocuous and noxious cold, as well as cooling agents such as menthol (Julius, 2013; 
Takashima et al., 2010). Another family of voltage-independent channel are acid sensing 
channels (ASICs). They are activated by acidic pH and when activated are permeable to Na+ 
causing depolarization and secondary accumulation of Ca2+. Nerves expressing ASICs 
primarily innervate muscle, joint and bone (Wemmie et al., 2013). To detect mechanical 
sensation, the general consensus is that pressure opens a mechanosensitive cation channel to 
elicit rapid depolarization (Basbaum et al., 2009). However the molecular basis of 
mechnotransduction is far from clarified. It is a clinically highly relevant subject since 
mechanical hypersensitivity is a major problem for many pain patients. Several types of ion 
channels have been implicated in mechanotransduction, including TRP, DEG/EnaC (ASICs), 
and Piezos, but their exact role in nociceptive signaling remains illusive (Basbaum et al., 
2009; Ranade et al., 2015). 
There is a unique repertoire of voltage gated ion channels that are vital for controlling the 
excitability of the nociceptor and propogation of the signal. The key determinants of 
excitablity are Nav channels, like Nav1.7, Nav1.8, and Nav1.9, which have some differences in 
localization and receptor properties. For example, Nav1.8 has a higher threshold activation 
than Nav1.7, but carries most of the current underlying the depolarization phase of the action 
potential in C-type neurons (Benarroch, 2015; Renganathan et al., 2001). Navs are the target 
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of local anestethics, such as lidocaine, which effectively blocks the propogation of nociceptor 
signaling. Nociceptors express several subtypes of K+ channels, including Kv, that dampen 
the excitability of the nerve by regulating membrane potential, action potential threshold, as 
well as shape, firing frequency and adaptation (Tsantoulas and McMahon, 2014). 
Nociceptors in addition express several types of voltage-gated Ca2+ channels of L-, N-, and 
T-type. The α2δ subunit of high voltage gated Ca2+ channels, including the N-type channels, 
is of particular interest. This subunit is upregulated in models of neuropathic and 
inflammatory pain, and is the target of the analgesics gabapentin and pregabalin (Bauer et al., 
2010; Davies et al., 2007; Su et al., 2015). 
G protein-coupled receptors are cell surface proteins that are ligand activated and initiate 
intracellular signaling pathways that can affect the properties of the neuron by regulating 
excitability. They are often used to define the histological and functional identity of sensory 
neurons. Excitatory receptors for bradykinin, protease activated receptors, and prostaglandin 
E2 receptors, activate G-coupled adynelate cyclase – cAMP – PKA or PLC – DAG – PKC 
pathways that have a wide variety of intracellular effects, for example sensitization and 
activation of TRPV1 (Gold and Gebhart, 2010; Schaible et al., 2002). The are also examples 
of inhibitory GPCRs on nociceptors, including the µ, κ, and δ opioid receptors (Mousa, 
2003). Activation of the opioid receptors will reduce intracellular cAMP, activate Kv, and 
inhibit Cav, potently reducing excitability of the neuron. 
The neurotrophin NGF is required for survival and development of sensory neurons during 
embryogenesis, but is also produced during tissue injury and can directly activate peptidergic 
C-fibers producing hypersensitivity (Lewin and Mendell, 1993). The neurons express the 
high-affinity receptor TrkA but also the low-affinity receptor p75, and activation by NGF 
causes a rapid increase in TRPV1 activity. Additionally, the NGF protein is also internalized 
and transported to the nucleus, promoting expression of pronocicepve peptides and proteins 
like substance P, TRPV1, and Nav1.8 (Basbaum et al., 2009; Chao et al., 2003; Snider and 
McMahon, 1998). 
Cytokines and chemokines are an integral part of the inflammatory cascade, released from 
variety of celltypes in response to injury or infection. Several of the receptors for both 
cytokines and chemokines are present on nociceptors, and there is evidence for a direct 
involvment of them in the regulation of hypersensitivity in a number of experimental models 
of pain, as well as in humans (Abbadie et al., 2009; Ren and Dubner, 2010; Schaible et al., 
2010). Of relevance for this thesis (paper III), the chemokine IL-8 (mouse analogue CXCL1), 
a well-characterized chemo-attractant, directly activates or sensitizes nociceptors by acting on 
its receptor CXCR2, which is present on sensory neurons (Qin et al., 2005; Wang et al., 
2008; Zhang et al., 2013). The receptor activation modify Nav and Kv, as well as TRPV1 
function, to increase sensitization and excitability in sensory neurons (Dong et al., 2012; 
Yang et al., 2009).. 
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1.2.1.3 Neurobiology of bone and joint 
The joint, ligaments, fibrous capsule, meniscus, periosteum, synovial layer, and surrounding 
bone structures are innervated by sensory nerves (Aβ, Aδ- and C-fibers) and noxious 
sensation can be evoked from these structures by various factors (Schaible et al., 2009). 
Many of these fibers are silent nociceptors, i.e. nerve fibers that are only activated by injury 
or damage to the structures in connection with inflammation. Once active, these fibers can 
either be spontaneously active or have reduced thresholds such that previously ineffective 
stimuli, in either noxious or innocuous range, can evoke activity. In contrast to the skin, the 
majority of the sensory neurons innervating bone and joint are thinly myelinated TrkA+ 
and/or peptide rich CGRP fibers, with minor innervation of Aβ and TrkA- peptide poor fibers 
(Fig. 8) (Jimenez-Andrade et al., 2010; Zylka et al., 2005). In the bone marrow and cortical 
bone, the nerve fibers most often co-localize with blood vessels, while the periosteum is 
densely innervated in a grid pattern (Martin et al., 2007). Interestingly, the articular cartilage 
of the joint lack innervation of sensory nerve fibers, so pain resulting from damage to 
cartilage itself is likely initiated in adjacent structures, like subchondral bone and synovium 
(Mantyh, 2014; Schaible et al., 2009). This data underlines the importance of knowing the 
microenvironment of the disease process, not just for modeling in animal studies but also for 
choosing pharmacological targets in patients. 
 
 
Figure 8. Types of sensory nerve fibers innervating bone. Schematic illustration of the organization and 
pattern of innervation of the bone. The types of sensory neurons that innervate the bone are unmyelinated C 
fibers and thinly myelinated Aδ fibers. The relative density of sensory fibers is greatest in the periosteum, 
followed by bone marrow and then cortical bone (A). Primary afferent neurons innervating bone have their cell 
bodies in the DRG and project to the spinal cord. The great majority (>80%) of the bone innervating sensory 
fibers express TrkA (the receptor for NGF), while <30% of the nerve fibers that innervate the skin express TrkA 
(B). Adapted from (Mantyh, 2014). 
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1.2.1.4 Peripheral and central sensitization 
Inflammation or injury such as fracture is characterized not just by activation of the 
nociceptive system but also by increased sensitivity to stimulation, a process that starts within 
minutes and can persist for months (Schaible et al., 2009). This is caused by several factors, 
described above, that cause altered activation thresholds of nociceptors, giving rise to 
hyperalgesia (increased pain intensity in response to a normal painful stimulus) and allodynia 
(pain due to a stimulus that does not normally provoke pain). Sensitization also includes an 
increase of suprathreshold response, spontaneous discharges, and increases in receptive field 
size of the nociceptive neurons (Grigg et al., 1986; McDougall, 2006; Schaible and Schmidt, 
1985).  
During persistent input, several changes also take place at the central level (dorsal horn) that 
amplify the nociceptive signal. It is a complex process that involves many types of cells and 
circuits, involving augmenting glutamatergic transmission and activation of glia cells (Tsuda 
et al., 2003; Woolf, 1983; Woolf and Salter, 2000). Interestingly, several of the molecules 
released in the periphery during inflammation, like TNF and IL-6, are also released by glia 
during activation, contributing to the central sensitization. In addition to enhancing the 
peripheral input, central sensitization contributes to the painful sensation around the original 
site. This secondary hyperalgesia involves heterosynaptic facilitation, where normally 
innocuous inputs, for example Aβ efferents normally responding to light touch, now signal 
into nociceptive circuits producing mechanical allodynia (Basbaum et al., 2009; Campbell et 
al., 1988). Additionally, factors released during dorsal horn activity can cause inhibitory 
neurotransmittors to depolarize rather than hyperpolarize neurons, further amplifying the 
nociceptive signaling (Coull et al., 2005).To prevent establishment of a hyperexcitable 
nociceptive pathway, it is important to understand how the peripheral signal originates, which 
is the main focus of this thesis. 
 
1.2.2 Pharmacological pain management in RA 
There are several pharmacological options for treating pain in RA, both direct acting 
analgesics and indirectly reducing the disease activity and inflammation. Unfortunately, 
despite optimal disease control, pain can remain a major problem (Altawil et al., 2016; Lee et 
al., 2011; McWilliams et al., 2012).  
Suppression of joint inflammation and associated pain can be achieved using a variety of 
drugs. Traditional treatments for arthritis like glucocorticoids and methotrexate have 
documented beneficial effect on pain by reducing synovial inflammation (Kirwan and Boers, 
2004; Williams et al., 1985). Due to side effects, steroid use is limited and symptoms may 
return after discontinued use, while methotrexate is often better tolerated for chronic 
treatment. Biologic disease modifying anti-rheumatic drugs (DMARDs), like cytokine 
blockers, also reduce joint inflammation and pain (Keystone et al., 2004) and can have an 
additive effect on pain relief when administered as co-therapy with methotrexate (Weinblatt 
  17 
et al., 2006). Since inflammatory cytokines such as TNF and IL-6, can directly affect 
peripheral nociceptive neurons (Brenn et al., 2007; Sommer and Kress, 2004), part of the 
analgesic effect of patients experience is likely due to inhibiting the direct effect of the 
cytokines. In fact, analgesic effect from the TNF-blocker was reported to occur well before 
any reduction in inflammation (Rech et al., 2013). Similar results has also been reported in 
animal models of arthritis (Boettger et al., 2008; Hess et al., 2011). 
There are several types of analgesic drugs used in RA for pain management, for example 
non-steroid anti-inflammatory drugs (NSAIDs), paracetamol, opioids and opioid-like drugs, 
and neuromodulators (anticonvulsants, antidepressants, and muscle relaxants). However, the 
number of well-performed clinical trials focusing on pain is limited, and the trials done show 
limited efficacy, especially beyond 6 weeks (Walsh and McWilliams, 2014). Long-term use 
also increases risks of side effects, making analgesic treatment a constant balance between 
the risk and benefit for the patient and often limiting its use (Walsh and McWilliams, 2014; 
Whittle et al., 2012). Additionally, there are few clinical studies on the safety of using 
analgesic in patients with comorbidities like gastrointestinal or cardiovascular disease 
(Radner et al., 2012). Combining different classes of analgesics can sometimes have a 
synergistic effect, thus achieving better pain control than with monotherapy, although with 
possible increased risk of side effects. A recent review of pain management in neuropathic 
pain showed evidence of improvement in pain control with combination therapy (Finnerup et 
al., 2010). Unfortunately, there is insufficient evidence from clinical trials in RA to make 
similar recommendations (Ramiro et al., 2011). Despite the limitations of analgesics, it is 
important that patients can decide their treatment based on informed choices and individual 
preference. It is also important to thoroughly study which pain mechanisms are active in 
patients to make recommendations for treatments. For example, pain in patients without an 
inflammatory component are unlikely to get relief from NSAIDS. 
 
1.3 EXPERIMENTAL ARTHRITIS 
Since many factors are unknown in the pathogenesis of human RA, modeling the disease in 
animals is difficult. Frequently arthritis pain studies involve injection of a substance that 
causes inflammation, like carrageenan or complete Freund’s adjuvant (CFA). These 
substances produce robust inflammation and subsequent pain behavior in rodents but are 
relatively short lasting, from a few hours up to 1-2 weeks. Injection of these substances into 
the joint cavity causes infiltration of immune cells and synovial hypertrophy but other aspect 
of RA, like bone erosion and cartilage erosion, are usually not present. Furthermore, RA is a 
systemic polyarthritis involving both innate and adaptive immune system, which may impact 
on how the sensory neurons in the joint are activated. Thus, monoarthritic models that 
activate predominately the innate immune system might not be the optimal way of studying 
pain in RA.  
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To enable studies to involve the complex pathology of RA, models involving immunization 
are sometimes used. This comprises inoculation with an antigen and adjuvant, causing 
breakage of immunological tolerance and a T- and B-cell driven reaction against the antigen. 
A widely used antigen is CII, called the collagen induced arthritis model (CIA) (Courtenay et 
al., 1980; Trentham et al., 1977). Inoculation with CII triggers the immune system to 
produce anti-CII antibodies leading to a chronic polyarthritis with RA-like joint pathology. 
CIA is generally considered a good model with features such as breaking of self-tolerance, 
targeted cartilage immunity, and T- and B-cell activity (Holmdahl et al., 1990; Wooley et al., 
1981), that have similar MHC II genetic association as human RA (Gregersen et al., 1987; 
Wooley et al., 1981). The CIA model results in robust and long-lasting pain behavior in 
rodents and has been used in several pain studies (Baek et al., 2005; Broom et al., 2008; 
Clark et al., 2012; Inglis et al., 2007; Kinsey et al., 2011; Nieto et al., 2015; Patro et al., 
2011). A drawback with the model is the progressive nature of the arthritis. Once initiated the 
inflammation and bone destruction will progress, not reflecting the human disease course and 
making it impractical for long-term behavior studies.   
1.3.1 Collagen antibody-induced arthritis 
The strong association of anti-CII antibodies and disease in CIA led to the development of the 
collagen antibody induced arthritis (CAIA) animal model (Nandakumar et al., 2003; Stuart 
and Dixon, 1983; L. Svensson et al., 1998; Terato et al., 1992), which Paper III explores 
from a sensory perspective. In the CAIA model the breaking of tolerance against CII is 
bypassed, reflecting the antibody-mediated effector phase of RA. It is induced by an 
intravenous or intraperitoneal injection of a mixture of anti-CII antibodies of IgG2a and 
IgG2b isotype. Lipopolysaccharide (LPS) is injected systemically 3-5 days after injection of 
CII antibodies in order to synchronize onset of joint inflammation and enhance disease 
severity and incidence by toll-like receptor 4 (TLR4) mediated activation of complement 
components and increased release of inflammatory mediators (Nandakumar et al., 2003; 
Terato et al., 1992). A polyarthritis resembling active CIA pathology develops, though with a 
faster onset (5-7 days), resulting in a transient inflammation lasting 3-4 weeks. Primarily 
small joints in the front and hind paws are affected but occasionally also knee and vertebral 
joints are involved. CAIA susceptibility is MHC independent and is able to manifest in 
strains resistant to CIA (Nandakumar et al., 2003; Stuart and Dixon, 1983). Mouse strains 
like DBA/1, B10.RIII, Balb/C and CBA, have high susceptibility (>90% incidence) while 
C57BL/6, B10.Q and NOD.Q have low susceptibility (<50% incidence), indicating a genetic 
dependence in incidence and severity (Nandakumar and Holmdahl, 2007). Mice lacking 
activating FcγRs (Kagari et al., 2003) or C5a signaling (Grant et al., 2002; Watson et al., 
1987) are resistant to CAIA. Interestingly, such mice still accumulate IgG and C3 on the 
cartilage surface but inflammation is not initiated (Grant et al., 2002), highlighting the 
importance of the innate immune system in the effector phase. The CAIA model is a tool to 
study the effector phase of arthritis but does not involve T and B cells that are part of the 
normal RA pathophysiology. The transient inflammation gives a good opportunity to study 
several phases of an RA flare (including pre- and post-inflammation). Interestingly, there is a 
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disconnection between inflammation and the pain behavior, as mechanical hypersensitivity is 
apparent before onset of inflammation (Agalave and C. I. Svensson, 2014; Bas et al., 2012). 
Paper III focuses on the role of collagen antibodies in the initiation of pain behavior in the 
pre-inflammatory phase. 
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2 AIMS OF THESIS 
The overall aim of the thesis is to explore mechanisms that drive initiation and maintenance 
of nociceptive signaling in autoimmune disease. Specifically how antibodies that are common 
in rheumatoid arthritis patients affect and interact with peripheral sensory neurons, in 
structures that are targeted in the disease: i.e. joint and bone. The thesis has two specific aims: 
1. To characterize the in vivo consequences of anti-citrulline immunity and identify the 
effects on nociceptive processing. 
 
2. To investigate the pain-like behavior in early phase of the CAIA model, with specific 
focus on the role of anti-CII antibodies in the initiation of sensory signaling. 
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3 MATERIAL AND METHODS 
3.1 ANIMAL MODELS 
3.1.1 Animals 
Animal experiments were approved by the local ethics committee for animal experiments in 
Sweden. Mice were housed in standard cages (3-5 per cage) in a climate controlled 
environment maintaining a 12 h light/dark cycle with access to food and water ad libitum. 
Several strains of mice have been used for the work in this thesis. For Paper I and II Balb/C 
and B10.RIII were used. For Paper III B10.RIII, B10.Q, and Balb/C were used. Additionally, 
several genetically modified mice were also used in Paper III: B10.Q C5-/-, which are mice 
with a natural complement component 5 mutation leading to a complete deficiency; 
B10Q.ACB (Anti-C1 B-cell) (Cao et al., 2011) which is a germline encoded anti-CII B cell 
knock-in strain with spontaneous production of anti-CII IgG; ACB C9-/-, which are ACB 
mice lacking cartilage matrix protein collagen type IX (C9); Fcγ chain -/-, which are mice 
lacking the common γ-chain and thus, have no functional activating FcγRs. 
3.1.2 Injection of autoantibodies 
3.1.2.1 ACPA 
Human and mouse antibodies that bind to citrullinated epitopes were used in paper I and II, as 
a novel model of ACPA-induced pain behavior. Mice were injected i.v. with 0,125-4 mg of 
human IgG and 2 mg of murine IgG in 100-150 µl saline. The donors were patients visiting 
the Rheumatology clinic at Karolinska University Hospital, who fulfilled the ACR/EULAR 
criteria for RA. They were tested for anti-CCP2 reactivity and samples were collected from 
ACPA+ patients, ACPA- patients, and also healthy controls. Plasma, sera, and synovial fluid 
were collected and kept at -80°C until processed. 
To purify the collected human antibodies, samples were centrifuged at 3000 g for 5 minutes 
and diluted 1:5 (v/v) in PBS. IgGs were purified from diluted plasma and sera on HiTrap 
Protein G HP columns. Eluted IgGs were dialyzed against PBS and the antibodies from 
ACPA+ RA patients were applied to the CCP2 affinity column. ACPAs were eluted using 0.1 
M glycine–HCl buffer (pH 2.7) and the pH was directly adjusted to 7.4 using 1 M Tris (pH 
9). IgGs not binding to the CCP2-column were used as control in control experiments, they 
were denoted as flow through (FT). Autoantibodies were concentrated and the buffer 
exchanged to PBS using the 10 kDa Microsep™ UF Centrifugal Device. Recovery and purity 
of total ACPAs were analysed by SDS-PAGE followed by Coomassie Blue staining and anti-
CCP2 reactivity. The concentration (mg/ml) of total IgG was calculated based on the initial 
plasma/sera volume applied to the Protein G column and the amount of IgG eluted from the 
column. The endotoxin levels were determined in the different pools of autoantibodies by the 
limulus amebocyte lysate assay and the cut-off for positivity was assumed as > 0.05 EU/ml. 
Three different ACPA pools were utilized for the in vivo experiments (paper I and paper II): 
ACPA pool 1 containing autoantibodies purified from 38 plasma samples, ACPA pool 2 
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containing autoantibodies from 6 plasma/sera samples and ACPA pool 3 that includes 
autoantibodies purified from 25 plasma/sera samples. To prepare the ACPA+ pool, antibodies 
isolated from the same plasma/sera samples as used for ACPA pool 2 were selected. This 
pool of antibodies was constituted by ACPA and non-ACPA IgGs. 
Additionally, monoclonal ACPA were used in paper I and II. Production of murinized 
monoclonal antibodies D10, B2, C7 and E2 is described in detail in (Amara et al., 2013). In 
brief, single B-cells were sorted from synovial fluid of ACPA+ patients into a 96-well plate. 
Digested PCR products from single cells were cloned into expression vectors containing 
Igγ1, Igκ, or Igλ constant regions and transfected into human embryonic fibroblasts HEK293. 
Supernatants were collected and purified by binding to protein G-sepharose column and 
expression of heavy and light chain, as well as purity, was verified by PAGE. Reactivity of 
the generated monoclonal antibodies against citrullinated and native form of α-enolase (CEP-
1), vimentin (aa 60-75), and fibrinogen (aa 36-52) peptides was determined with ELISAs. 
The E2 antibody (also derived from a RA synovial B cell) reacts against human tetanus and 
was detected using ELISA. Murinization of the human monoclonal antibodies was performed 
by replacing the full human IgG1 Fc by the murine IgG2a Fc. Mouse monoclonal ACC4 is 
produced in hybridoma generated from mice immunized with PAD4-treated CII. The 
generated antibody binds the citrullinated C1 epitope on CII as an α-chain peptide and 
interacts directly with citrulline as shown earlier with crystal structure (Uysal et al., 2009). It 
also cross-reacts with the cyclic citrullinated filaggrin peptide (CCP1), but not with non-
citrullinated forms of CII. 
3.1.2.2 Collagen type II antibodies 
Our normal CAIA protocol consist of a lipopolysaccharide (LPS) injection 5 days after 
injection of antibodies, to induce inflammation. In Paper III, that protocol was used in one 
experiment. Subsequent experiments focused on the pre-inflammatory phase, so LPS was not 
injected. Mice were given i.v. injections on day 0 with either saline or anti-CII mouse 
monoclonal antibodies (mAbs) (4 mg in a total volume of 150 µl saline). Arthritogenic anti-
CII mAbs; M2139, CIIC1, CIIC2, and UL1 (Nandakumar and Holmdahl, 2005) were 
injected either as a cocktail (1 mg/each) or as single antibodies (0.5-4 mg). In addition, the 
non-arthritogenic anti-CII mAb CIIF4 (Croxford et al., 2010; Nandakumar et al., 2008), as 
well as IgG2a and IgG2b isotype control mAb were used. Antibodies were produced and 
purified as described earlier (Nandakumar and Holmdahl, 2005). Lipopolysaccharide was 
used in one experiment and injected intraperitoneally (i.p.) 5 days after injection of anti-CII 
mAb cocktail. 
In several experiments modified antibodies were used. To remove the N-linked glycans, 
M2139 mAb was incubated with recombinant endo-β-Nacetylglucosaminidase (EndoS) fused 
to glutathione S-transferase (GST) as previously described (Collin and Olsén, 2001). Briefly, 
GST-EndoS in phosphate buffer solution (PBS) was mixed with M2139 mAb and incubated 
at 37°C for 16 h. GST-EndoS was then removed using Glutathione- Sepharose 4B columns. 
Further purification of the antibodies was done using an ion exchange column. SDS/PAGE 
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and Lens culinaris agglutinin (LCA) lectin blotting were used to confirm complete removal 
of GST-EndoS and efficacy of EndoS cleavage. Fab fragments were prepared from the anti-
CII mAb cocktail using Pierce Fab Preparation Kit according to the manufacturer’s 
instructions. Fab fragments and EndoS treated antibodies corresponding to 4 mg anti-CII 
mAb cocktail were injected i.v. 
Table 2 Antibodies used in the thesis 
Antibody Epitope Type Other information 
Human ACPA CCP2 Human Polyclonal IgG (Ossipova et al., 2014) 
Flow through (FT) Non-CCP2 Human Polyclonal IgG Control antibody (Ossipova 
et al., 2014) 
Healthy control (HC) Non selected Human Polyclonal IgG Control antibody 
1276:01:D10 CEP-1, cit-Fib, cit-vim Mouse IgG2a (Amara et al., 2013) 
1103:01:B02 CEP-1, cit-Fib, cit-vim Mouse IgG2a (Amara et al., 2013) 
1276:01:C07 CEP-1, cit-Fib, cit-vim Mouse IgG2a (Amara et al., 2013) 
1362:01:E02 Human tetanus Mouse IgG2a Control antibody (Amara et 
al., 2013) 
M2139 J1 epitope on CII Mouse IgG2b (Nandakumar and 
Holmdahl, 2005) 
CIIC1 C1 epitope on CII Mouse IgG2a (Nandakumar and 
Holmdahl, 2005) 
CIIC2 D3 epitope on CII Mouse IgG2b (Nandakumar and 
Holmdahl, 2005) 
UL1 U1 epitope on CII Mouse IgG2b (Nandakumar and 
Holmdahl, 2005) 
CIIF4 F epitope on CII Mouse IgG2b Anti-inflammatory 
(Nandakumar et al., 2008) 
ACC4 Cit-C1 epitope on CII Mouse IgG1 (Uysal et al., 2009) 
IgG2a control Human HLA-DRa Mouse IgG2a Control antibody 
IgG2b control Human parathyroid 
epithelial cells 
Mouse IgG2b Control antibody 
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3.1.3 Arthritis score and arthritis incidence 
The development of arthritis in the fore and hind paws was monitored by visual inspection as 
described previously (Bas et al., 2012; Nandakumar et al., 2003). Briefly, visible signs of 
inflammation, defined as redness and swelling, were scored on a 0–60 scale by investigators 
blinded to the origin and treatment of the mice. Each inflamed digit was noted as 1 point and 
inflammation of the metacarpus/metatarsus and ankle joint as 5 points, giving a maximum of 
15 points per paw. Incidence is calculated as percentage of mice that were positive for 
arthritis. Toes had to be inflamed at least two consecutive days to be defined as arthritic, to 
avoid false positives due to loss of nails etc. 
3.1.4 Pharmacology 
In Papers I and II, mice were treated with the CXCR1/2 antagonist reparixin (L-lysin salt), 
which was injected subcutaneously (s.c. in 100 µl saline) twice daily (30 mg/kg/day).  
In Paper III mice were treated with the cyclic peptide C5a-receptor inhibitor (PMX53, s.c., 3 
mg/kg in saline) 1 h prior to injection of anti-CII mAb cocktail and then once daily 3 h prior 
to assessment of mechanical hypersensitivity for 5 days. 
3.1.5 Metalloprotease activity 
Mice injected with either saline, 1 mg hACPA, or 4 mg anti-CII IgG received i.v. injection of 
MMPsense 680 (2 nmoles in 150 µl PBS/mouse) 24 h before sacrifice. Paws were removed 
and scanned in an Odyssey CLx (LI-COR) near-infrared system. The signal intensity was 
quantified and normalized to saline injected mice and the data presented as a heat map. 
 
3.2 ASSESSMENT OF PAIN-LIKE BEHAVIOR 
Mechanical and thermal sensitivity in the hind paws and reduced locomotion were used as 
measures of evoked and spontaneous pain-like behavior, respectively. Assessment of 
mechanical and thermal sensitivity was performed on indicated days and locomotion was 
assessed during the third night after antibody injection. Mice were allocated to have even 
baseline tactile thresholds across treatment groups. The investigators were blinded for the 
origin and treatment of the mice during behavioral assessments, until after analysis of the 
results. 
3.2.1 Mechanical sensitivity 
The mice were habituated in individual compartments on top of a wire-mesh surface (Ugo 
Basile) prior to experiment. On test days, mice were given time to acclimatize and then 
optiHair filaments of increasing buckling force (0.5, 1, 2, 4, 8, 16, and 32 mN) were applied 
to the plantar surface of the paw until the filament bent slightly. A brisk withdrawal of the 
paw within 2-3 seconds was noted as a positive response. A 50% withdrawal threshold was 
calculated using the Dixon up-down method (Chaplan et al., 1994) and results from both 
hind paws were averaged and presented as % of baseline values. After unilateral intra-
articular injections only the result from the ipsilateral paw was used. In addition to presenting 
the results as 50% withdrawal threshold in Paper I, data were also presented as an algesic 
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index, a calculation that defines the effect of reparixin treatment. It represents the area (based 
on withdrawal threshold in percent and time in days) between the extrapolated line from start 
of treatment (day 6) and the time–response curve after reparixin or saline injection. Increasing 
values indicate decreasing hypersensitivity. 
3.2.2 Heat sensitivity 
Heat sensitivity was examined using a modified Hargreaves box (Dirig et al., 1997). Mice 
were placed individually in Plexiglas cubicles on the glass surface and allowed to habituate. 
A radiant heat stimulus, which was a fixed distance beneath the glass, was aimed at the 
selected hind paw until a motion sensor detected a brisk withdrawal, which ended the 
stimulus. Elapsed time is automatically recorded with a cutoff at 20 s to prevent tissue 
damage. Three measurements from each paw were averaged and presented as latency (in 
seconds) of the withdrawal. 
3.2.3 Cold sensitivity 
To assess sensitivity to cold, the mice were placed in the same testing device as used for 
detection of mechanical hypersensitivity. After habituation a 1 ml syringe was used to gently 
apply a drop of acetone to the plantar surface of the hind paw and the duration of the 
nocifensive behavior (lifting, shaking, biting, and licking the paw) was recorded. The test was 
repeated three times on each paw, with at least 5 min between tests, and the average was 
calculated. 
3.2.4 Locomotion 
Food and water consumption, and activity level of the mice during a full night cycle was 
measured using an Oxymax/Comprehensive Lab Monitoring System (CLAMS). Mice were 
habituated for 24h in individual testing cages before being moved into the CLAMS just 
before the start of the night cycle (18:00-06:00). Infrared sensors detected movement in X, Y 
and Z-axes and recorded number of beam breaks during the testing period. These values were 
then summed to show total movement over the whole 12 h night cycle. A feeder system 
connected to a scale and automated water device recorded consumption during the period. 
The data is presented as total movement (total number of XY-axis beam breaks), ambulation 
(number of consecutive XY-axis beam breaks), rearing (number of beam breaks in the Z-
axis), food intake (g), and water intake (ml) 
 
3.3 CELL CULTURE 
3.3.1  Osteoclast cultures and chemokine analysis 
For in vitro osteoclasts generation, bone marrow cells were obtained from wildtype Balb/c 
mice and CD-11b+ cells were then isolated using anti-CD-11b microbeads. CD-11b+ cells 
were seeded with 280x105 cells per well in DMEM containing 10% heat inactivated fetal 
bovine serum (FBS), 2mM L-glutamine, 100 IU/ml penicillin and 50 µg/ml streptomycin and 
stimulated with M-CSF 25 ng/ml and RANKL 25 ng/ml. From day 6, either saline, ACPA, or 
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FT was added to the media (1 µg/ml), which was replenished every two days with fresh 
supplements.  
Osteoclasts were analyzed using Tartrate-resistant acid phosphatase (TRAP) staining with a  
leukocyte acid phosphatase kit 387A following manufacture instructions. TRAP positive cells 
with not less than 3 nuclei were counted manually as osteoclasts in the Nikon inverted light 
microscope. 
Level of CXCL1 (KC-GRO) and CXCL2 (MIP-2α) was measured in the supernatants from 
the cultured cells and were analyzed using V-Plex immunoassay kit (Meso Scale Discovery) 
for CXCL1 and ELISA kit for CXCL2, diluted 1:2 in assay diluents and according to 
manufacturers protocol. Limit of quantification (LOQ) was 0.8 pg/ml for CXCL1 and 7.8 
pg/ml for CXCL2. 
3.3.2 DRG cell culture 
In Paper I and III, several studies are based on in vitro studies on cultures DRG cells. The 
DRGs (L6-C1) from Balb/c mice were extracted and placed in ice-cold Dulbecco`s PBS until 
they were enzymatically dissociated with papain (1.7 mg/ml) (30 min at 37°C) followed by a 
collagenase I (2 mg/ml) and dispase II (8 mg/ml) enzyme mix (30 min at 37°C). The cells 
were then gently triturated in Leibovitz`s medium supplemented with 10% heat-inactivated 
bovine serum, 1% penicillin and streptomycin (Invitrogen) and 10 µM mitotic inhibitor (5-
fluoro-2-deoxyuridine). The cell suspension was plated on uncoated well plates for 1.5-2 h 
before transferred to poly-D-lysine and laminin pre-coated well plates. The cells were 
maintained at 37°C in 5% CO2 atmosphere and the medium replaced after 24 h and then 
every third day. For functional experiments, immune complexes were applied to the cultures. 
Collagen II mAb immune complex (CII-IC) stock solution (1 mg/ml) was prepared by mixing 
anti-CII mAb cocktail (1 mg/ml) with rat CII (1 mg/ml, detailed in (Burkhardt et al., 2002), 
at a ratio of 1:1 at 37°C with gentle shaking for 30 min.  
3.3.2.1 CGRP release 
After 6 days in culture, the medium was removed and the cells were washed twice with 
HEPES buffer (25 mM HEPES, 135 mM NaCl, 3.5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 
3.3 mM dextrose, 0.1% (w/v) bovine serum albumin, pH 7.4 with NaOH) and placed in new 
HEPES buffer for 30 min at 37°C (pre-stimulation). The HEPES buffer was collected for 
analysis of basal CGRP release. The cells were then incubated with CII-IC (0.1, 1 and 10 
µg/ml), anti-CII mAb cocktail, CII antigen, or control IgG2b (1 µg/ml) in HEPES buffer or 
HEPES buffer alone for 30 min at 37°C (post-stimulation) and the supernatant was collected 
for CGRP analysis. Capsaicin (50 nM) in HEPES (10 min at 37°C) was used as a positive 
control. CGRP levels (pg/ml) in the supernatants were determined with enzyme immune 
assay (EIA) kit in accordance with the manufacturer's instructions. The % change between 
pre and post-stimulation was calculated for each well. 
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3.3.2.2 Calcium imaging 
After 24 and 48 h in culture, the cells were loaded with Fluo-3 (4.4 µM) for 30-40 min at 
room temperature (20–22 °C). The cells were washed with modified HEPES buffer (145 mM 
NaCl, 3 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM Glucose and 10 mM HEPES, pH 7.4 
with NaOH) and then placed in the recording chamber and continuously perfused with bath 
solution (modified HEPES buffer) at a constant flow rate (1 ml/min). The calcium imaging 
was performed using a Nikon Diaphot inverted microscope with a diode laser 488 nm 
excitation and a 40X oil immersion objective. The change in emission (506 nm) i.e. 
intracellular calcium bound to Fluo-3 was recorded every 15-20 s using a PMT. Human 
ACPA (1 µg/ml) or control FT (1 µg/ml) was applied for 5 min to the same cells with a 
minimum of 10 min wash period between applications. At the end of each experiment 50 mM 
KCl was applied for 1 min as a control. All reagents were prepared from stock solutions and 
dissolved in modified HEPES buffer. Images were analyzed with ImageJ software. In each 
image, capturing in average 10 cells, all visible cells were chosen for analyses. Mean 
fluorescence intensity (F) for the region of interest (ROI), the cell bodies, was measured in 
each image. F0 was calculated as the average mean intensity of the first 7 images in each 
series and the data presented as F/F0. 
3.3.2.3 Electrophysiological recordings 
Whole cell patch-clamp recordings were performed at room temperature (20–22 °C) within 
24 and 48 h of culturing using an Axo-Patch-200A amplifier filtered at 1 kHz and sampled at 
4 kHz and analyzed Clampex 10.4.software. Patch pipettes were pulled from borosilicate 
glass capillaries (1.5 mm outer diameter, 0.86 mm inner diameter) using a vertical puller. The 
resistance of the patch pipettes was 4–5 MΩ when filled with internal solution (120 mM K+-
gluconate, 20 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 11 mM EGTA, 10 mM HEPES, 2 mM 
NaATP, pH 7.15 with Tris-base). Voltage-clamp recordings were conducted in small DRG 
neurons (15-25 µm in diameter) using the whole-cell configuration. Series resistance was not 
compensated. DRG neurons were continuously perfused with oxygenated bath solution 
(modified HEPES buffer) at a constant flow rate (1-1.5 ml/min). Human ACPA (1 µg/ml) 
was applied for 1 min and capsaicin (0.5 µM) was applied at the end of each recording for 10 
s as a control (4 min wash period between applications). Cells having a resting membrane 
potential more negative than -40 mV were accepted. All reagents were prepared from stock 
solutions and dissolved in modified HEPES buffer and applied via an 8-channel pressure-
controlled application system. 
 
3.4 TISSUE ANALYSIS 
3.4.1 Joint histology 
Mice were deeply anesthetized with pentobarbital (50 µg/kg) and perfused intracardially with 
saline followed by 4% PFA. After perfusion, hind legs were post-fixed in 4% PFA for 48 h, 
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then decalcified in 10% ethylenediaminetetraacetic acid (EDTA) in a PBS (pH 7.4) at 4o C 
for 4-5 weeks, with changes of EDTA every 7 days. Tissues were then dehydrated in ethanol 
and embedded in paraffin. Sections (5 µm) were stained with hematoxylin and eosin and 
scored by blinded investigators as previously described (Bas et al., 2012) on a scale from 0-3, 
where 0 is normal and 3 is severe synovitis, bone erosion, and/or cartilage destruction. 
3.4.2 Joint and bone immunohistochemistry 
Following decalcification as above, each joint was cryoprotected in 30% sucrose at 4o C for at 
least 48 hours before being sectioned. To assess the binding of ACPA in different cell 
populations, either 30 µm-thick frozen sections of the bone/joint were obtained using a 
cryostat or mouse bone marrow cultures grown on glass slides, were used. Then, slides were 
dried at room temperature (RT) for 30 minutes, washed in 0.01M PBS three times for 10 
minutes each, blocked with 3% normal goat serum (NGS) in PBS with 0.3% Triton-X 100 for 
60 minutes and then incubated overnight with ACPA (5 µg/ml) with different primary 
antibodies made in 1% NGS and 0.1% Triton-X 100 in 0.01M PBS at RT.  Blood vessels 
were labeled with an antibody against platelet endothelial cell adhesion molecule (rat anti-
mouse PECAM, 1:500, BD PharMingen). Macrophages and osteoclasts were identified with 
an antibody against a single-chain glycoprotein of 110 kDa that is expressed predominantly 
on the lysosomal membrane of myeloid cells (rat anti-mouse CD68; 1:2000). Multinucleated 
CD68-positive stained and located within the mineralized bone-lining zone were considered 
to be osteoclasts. Primary afferent sensory nerve fibers were labeled with an antibody against 
calcitonin gene-related peptide (CGRP, polyclonal rabbit anti-rat CGRP; 1:5,000). After 
primary antibody incubation, slides were washed 3X10 minutes in PBS and incubated for 3 
hours at RT with respective (488 and 594) Alexa-conjugated secondary antibodies (1:300). 
Sections were washed in 3X10 minutes in PBS and counterstained with DAPI (1:20,000) for 
5 minutes. After this, preparations were then washed 3X10 minutes each in PBS, dehydrated 
through an alcohol gradient (70%, 80%, 90%, and 100%) for 2 minutes each wash, cleared in 
xylene for 2 minutes, and cover slipped with di-n-butylphthalate-polystyrene-xylene.  
3.4.3 DRG and Spleen immunohistchemistry and immunocytochemistry 
Mice were deeply anesthetized with pentobarbital (50 µg/kg) and perfused with saline 
followed by 4% paraformaldehyde (PFA). Following perfusion, the lumbar DRGs (L4-L6) 
and spleen were dissected, post-fixed (3 h for DRG, overnight for spleen) in 4% PFA, 
cryoprotected in 20% sucrose for two days and then frozen in OCT. The tissues were stored 
in -70°C until cryo-sectioned (12 µm) and mounted on glass slides. Cultured DRG primary 
cells were fixed in 4% PFA for 10 min 48 h after culturing and then stored in PBS at 4°C 
until stained. Non-specific binding in sections and cultured cells was blocked using 5% 
donkey serum in PBS. Tissues and cells were incubated with the primary antibody overnight 
at 4°C and the immunoreactivity was visualized using secondary donkey antibodies 
conjugated to Alexa 488 or Alexa 594 (1:300). Prolong Gold antifade with DAPI, was used 
for cover slipping. Antibodies against the following proteins were used: FcγRI, FcγIIb, 
FcγIII, and FcγRIV (2 µg/ml, gift from dr Mark Cragg, Uni. of Southampton. Antibodies 
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characterized in (Tutt et al., 2015)), PGP9.5 (1:500), CGRP (1:10 000, gift from Prof T. 
Hökfelt, Karolinska Institutet, Stockholm), TRPV1 (1:100), Iba1 (1:1000), GFAP (1:1000). 
3.4.4 Confocal microscopy 
Confocal images were acquired with a LSM710 confocal laser-scanning microscope operated 
with ZEN2012 software (Zeiss). Nuclear staining using DAPI; a fluorescent stain that binds 
strongly to A-T rich regions in DNA was visualized using an excitation beam of 405 nm and 
emissions were detected using a BA430-470 emission filter. Sequential acquisition mode was 
used to reduce bleed-through from fluorophores. Multipanel figures were assembled in 
Adobe Illustrator CS6 software. 
3.4.5 Western blot 
The presence of human IgG antibodies (ACPA, FT, and IgG from healthy controls) in mouse 
tissues and plasma was assessed by Western blotting. Joints (ankle), dorsal root ganglia, 
adipose tissue (subcutaneous white), skin (plantar hind paw), spleen, lung, skeletal muscle 
(quadriceps), heart, kidney, liver, spinal cord (L4-L6), brain and bone marrow (tibial) were 
homogenized with protein extraction buffer (0.5% Triton X-100, 50 mM Tris, 150 mM NaCl, 
1mM EDTA and 1% SDS, pH 7.4) supplemented with proteases inhibitors (GE Healthcare). 
Supernatants from the homogenates as well as sera were mixed with LDS sample buffer 
containing DTT, and denatured at 70°C for 10 minutes. Total proteins from the tissue 
homogenates and plasma (30 µg per well) were loaded onto NuPAGE® Bis-Tris 4-12% gels 
and run in MES-SDS antioxidant-containing running buffer at 200 V for 50 min. Proteins 
were transferred to a nitrocellulose membrane at 30V and blocked with 5% non-fat dry milk 
prepared in TBS containing 0.1% Tween 20 for 1 hour at room temperature. For the 
immunoblotting, membranes were incubated with the secondary antibody rabbit anti-human 
IgG HRP (1:10 000) for 1 hour at room temperature. The membranes were developed using 
the SuperSignal® West Pico chemiluminescent substrate, according to manufacturer’s 
instructions. 
3.4.6 Gene expression analysis 
3.4.6.1 Quantitative real-time polymerase chain reaction (PCR) 
Ankle joints and plantar paw skin of the hind legs were processed for gene expression 
analysis. Muscle and tendons were removed from ankle joints, which were then snap frozen 
and pulverized. Tissues were sonicated in TRIzol and RNA was extracted according to 
manufacturers protocol. After complementary DNA (cDNA) synthesis, quantitative real-time 
PCR was performed using hydrolysis probes to determine the relative messenger RNA 
(mRNA) levels. Primers for various genes (Table 3), including reference gene Hprt1, were 
used to determine threshold cycle values to calculate the number of cell equivalents in each 
sample with the standard curve method. Data is normalized to Hprt1 values and expressed as 
relative expression units (REU). 
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Table 3. Primers used for real-time PCR  
Gene Taqman primer 
Ccl2 (Mcp-1) Mm00441242_m1 
Cox2 Mm00478374_m1 
Cxcl1 Mm04207460_m1 
Cxcl2 Mm00436450_m1 
Cxcl5 Mm00436451_g1 
Hprt1 Mm01545399_m1 
Il1b Mm00434228_m1 
Il6 Mm00446190_m1 
Mcpt4 (Mcp4) Mm00487636_g1 
Mmp2 Mm00439498_m1 
Mmp9 Mm00442991_m1 
Mmp13 Mm00439491-m1 
Tnf Mm00443258_m1 
Tpsb2 (Mcp6) Mm01301240_g1 
 
3.4.6.2 Microarray expression analysis  
Lumbar DRGs (L4-6) were dissected and total RNA was extracted and purified using an 
RNeasy mini kit according to manufacturers instructions. RNA concentration was measured 
using an ND-1000 spectrophotometer and RNA quality was evaluated using the Agilent 2100 
Bioanalyzer system. 250 ng of total RNA from each sample was used to generate amplified 
and biotinylated sense-strand cDNA from the entire expressed genome according to the 
Ambion WT Expression Kit and AffymetrixGeneChip® WT Terminal Labeling and 
Hybridization User Manual. GeneChip® ST Arrays were hybridized for 16 h in a 45°C 
incubator, rotated at 60 rpm. According to the GeneChip® Expression Wash, Stain and Scan 
Manual the arrays were then washed and stained using the Fluidics Station 450 and finally 
scanned using the GeneChip® Scanner 3000 7G. The raw data was normalized in the free 
software Expression Console provided by Affymetrix using the robust multi-array average 
(RMA) (method first suggested by (“Model-based analysis of oligonucleotide arrays: 
Expression index computation and outlier detection,” 2001)), followed by extraction of the 
expression levels of the genes of interest (Fcgr1, Fcgr2b, Fcgr3 and Fcgr4). For human 
comparison, the gene expression levels (GeneChip® Human Genome U133 Plus 2.0) from 
eight donor human dorsal root ganglia, of the corresponding human genes (FCGR1C, 
FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCGR3B and reference genes TRPV3, TRPV4, 
HTR3C), were extracted from the ArrayExpress publically available gene expression set 
(Roth et al., 2006). 
3.4.6.3 Single-molecule fluorescence RNA in situ hybridization (smFISH) 
smFISH was carried out as previously described (Zeisel et al., 2015) with some 
modifications. DRG from mice were collected and frozen in OCT. After cryosectioning, the 
sections were post-fixed in 4% PFA, and stored in -80°C until use. For hybridization, the 
sections were first permeabilized for 10 min with methanol in -20°C and incubated with 250 
nM fluorescent labeled probes for 4h at 37°C and counterstained with DAPI. The sections 
were mounted with Pro-long Gold and image stacks (0.3 µm distance) were acquired using a 
customized automated scanning microscope controlled by µManager. Images were analyzed 
using a custom Python script. After background removal, a Laplacian-of-Gaussian was used 
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to enhance the RNA dots that were identified by computing the extended maxima-transform 
of the flattened image. 
 
3.5 STATISTICS 
For comparing changes over time, repeated measures two-way analysis of variance 
(ANOVA) was used followed by a Bonferroni post-hoc test. For differences in three groups 
or more, a one-way ANOVA was used, followed by a Bonferroni post-hoc test. For 
differences in two groups, Students t-test was used. Arthritis and histological scores were 
compared using the Kruskal-Wallis test followed by Dunn’s multiple comparison post hoc 
test. All tests were performed using GraphPad Prism 6 software. P values less than 0.05 were 
considered significant. No statistical method was used to pre determine sample sizes. 
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4  RESULTS 
The work in this thesis is divided into two main projects involving pain and autoantibodies: 
Paper I and II investigating effects of anti-citrulline immunity, and Paper III the role of anti-
collagen antibodies. 
4.1 THE ROLE OF ANTI-CITRULLINATED PROTEIN ANTIBODIES 
ACPA has been thoroughly studied in regard to involvement in arthritis, but there is little 
evidence for a direct role in inflammatory pathogenesis. The interest to study ACPA from a 
sensory perspective originated because of certain features of the antibodies: they are 
commonly present in patients years before onset of RA, a period associated often with 
arthralgia, and the more recent discovery that they are linked to increased osteoclast (OC) 
activity and subsequent bone erosion.  
4.1.1 ACPA induce pain-like behavior in mice 
We started by comparing the effect of ACPA+ and ACPA+ IgG from RA patients on 
mechanical sensitivity of mice. Only antibodies from ACPA+ RA patients induced pain-like 
behavior in the mice. We then separated the IgG pool into ACPA and non-ACPA (FT), and 
determined that only the ACPA pool induced pain-like behavior. This included increased 
mechanical and thermal sensitivity, as well as reduction in locomotion. Importantly, there 
was no visual sign of inflammation in the mice, and there was no display of inflammation-
related sickness behavior like piloerection, weight loss or reduced feeding. Thus, we 
concluded that the observed effects were a consequence of the pro-nociceptive effect of 
ACPA (Fig. 9). Additionally, we also tested murinized monoclonal ACPA that were cloned 
from single B cells from RA patients and tested for CCP reactivity. These antibodies were 
also able to induce pain-like behavior in the mice, meaning that the observed effect was not 
associated with a reaction against human protein. 
 
  35 
Figure 9. Behavioral effects after injection of human antibodies. Mechanical sensitivity in mice 
after injection of IgG from healthy donors, IgG from patients with ACPA- or ACPA+ RA (A), purified 
ACPA or non-ACPA (FT)(B). Arthritis scores (0-60) in injected mice (C). Thermal sensitivity and 
changes in total movement in mice injected with ACPA or FT (D-F). 
 
4.1.2 ACPA accumulate in joints and bone marrow but does not directly 
increase neuronal excitability or induce signs of inflammation 
To investigate how ACPA induce pain-like behavior, we first wanted to determine where the 
antibodies go in the mouse. This was done by perfusing the mice with saline to eliminate the  
blood and then performing Western blots on the tissues, to detect human IgG. We found that 
IgG from healthy controls and FT distributed similarly in most tissues, while ACPA had a 
more restricted localization to joint, tibial bone marrow, and skin. Importantly, there were no 
antibodies in the CNS, indicating that induction of nociception is from peripheral locations. 
Many ACPA are produced by B cells in the arthritic synovia thus affinity maturation is 
driven by local antigens, but their preference to that location in naïve mice is an interesting 
observation.  
Next we wanted to examine the effects of the antibodies. An obvious possibility is that ACPA 
directly activate sensory neurons, causing nociceptive signaling. To test this we applied the 
antibodies to cultured DRG neurons, but ACPA did not induce intracellular Ca2+ or changes 
in membrane current, suggesting no direct effect on neuronal activity. Even though we could 
not visually detect inflammation, there is a possibility that low-grade inflammation could 
cause pain-like behavior. So we analyzed histological sections of tibial bone and joint, gene 
expression of inflammatory markers, and MMP activity, but there were no signs of cell 
infiltration, increased expression or activity of factor associated with inflammation. 
Noteworthy, however, Cxcl1 and Cxcl2 mRNA levels were elevated in ankle joint from 
ACPA, but not FT or saline-injected mice. These factors were not elevated in skin from the 
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plantar surface of the hind paw, which is important since we detected ACPA there and that is 
the region mechanical and thermal sensitivity is measured in the mice. 
4.1.3 ACPA bind osteoclasts and induce CXCL1/IL-8 release in mice and 
men 
In parallel work, we were investigating how ACPA interact with human OCs. It became clear 
from cell cultures that both polyclonal and monoclonal ACPA bound to OCs, and its 
precursors, causing both proliferation and increased calcium phosphate resorption. This 
process was dependent on PAD activity, since Cl-amidine, a pan-PAD inhibitor, was able to 
inhibit both the ACPA-induced proliferation and resorption. To investigate potential 
mediators responsible for the effect of ACPA, we analyzed the supernatant of the cultures for 
a common set of cytokines, including IL-6, TNF, and IL-10. Interestingly, all measured 
cytokines had low constant levels, except IL-8, which showed a significant increase with 
ACPA treatment. Adding exogenous IL-8 increased osteoclastogenesis and blockade of 
extracellular IL-8 with a neutralizing antibody inhibited the ACPA-induced OC formation, 
implicating IL-8 as a key mediator in the process. 
Importantly, using bone marrow cultures from mice we were able to show a similar pattern, 
ACPA bind OCs and induce release of CXCL1, which is the murine functional analogue of 
human IL-8. To connect the localization data with the in vitro effects, we wanted to 
determine the cellular targets of ACPA using immunohistochemical labeling of section from 
joint and bone (Fig. 10). This revealed that ACPA bind CD68+ cells with multinucleated 
morphology, proximal to mineralized bone, most likely OCs, as well as its precursors in the 
bone marrow. Interestingly, some ACPA+ cells were located in close proximity to CGRP+ 
sensory fibers in the bone marrow, showing a histological link. 
 
Fig 10. Binding of ACPA in bone 
marrow. Co-localization of ACPA 
with marker for 
macrophage/osteoclasts (CD68) in 
subchondral bone (A) and marker 
for sensory nerve fiber (CGRP) in 
tibial bone marrow (B). ACPA and 
CD68 binding in cultured mouse 
osteoclasts (C). Scale bar is 25 µm. 
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4.1.4  Pain-like behavior and bone erosion in mice is dependent on CXCL1/2 
We had several lines of evidence pointing towards OC activation and release of CXCL1 
explaining the ACPA-induced pain-like behavior, but we needed to show the connection in 
vivo. First we investigated the nociceptive effect of CXCL1/2, by injecting these factors into 
the ankle joint. This caused onset of robust mechanical hypersensitivity in the ipsilateral paw, 
confirming the nociceptive potential of the factors. To further examine the link to ACPA, we 
treated mice that had ACPA-induced thermal and mechanical hypersensitivity with the 
CXCR1/2 receptor antagonist reparixin. Six consecutive days of treatment partially reversed 
the mechanical and thermal hypersensitivity. Additionally, the tibia of the mice were 
analyzed using micro-CT revealing that ACPA induced erosions in the trabecular bone, 
which was inhibited by the reparixin treatment (Fig. 11). 
 
 
Figure 11. Effect of ACPA and treatment with reparixin on tibial bone parameters. 
Representative 2D micro-CT images of the tibial metaphysis of control mice (A) and mice that were 
injected with ACPA in the absence (B) or presence of reparixin (C). Graphs showing quantitative 
evaluation of the trabecular bone mineral density (BMD, D), trabecular number (E), bone volume 
fraction (bone volume/tissue volume, F) and the cortical tissue mineral density (TMD, G). 
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To summarize (Fig. 12), we propose a mechanism where 
ACPA bind to citrullinated antigens on osteoclasts, 
causing activation and release of CXCL1/IL-8. This 
causes increased proliferation and bone resorption by the 
osteoclasts. The CXCL1/IL8 activates and sensitizes local 
sensory neurons in the bone and joint, producing pain-like 
behavior manifested as reduction in the utilization of the 
joints, i.e. reduction in locomotion. The increased 
sensitivity also spreads to adjacent tissues, such as the 
plantar paw, reducing cutaneous thermal and mechanical 
thresholds for activation of the sensory fibers. This 
secondary hypersensitivity could be mediated either by a 
peripheral effect, where activity in a fiber can affect other 
fibers in the same nerve bundle (Sheth et al., 2002), or 
centrally by nociceptive circuit amplification and 
facilitation (Basbaum et al., 2009; Campbell et al., 1988). 
 
 
 
4.2 THE ROLE OF ANTI-COLLAGEN ANTIBODIES IN INDUCTION OF 
NOCICEPTION 
In our previous work with the CAIA model, we found that pain-like behavior is apparent 
several days before the onset of inflammation. We predicted that the early phase of the model 
would give us important information about the mechanisms that drive arthralgia in the “pre-
RA” phase. 
4.2.1 Induction of pain-like behavior is not associated with inflammation 
Our initial experiments aimed at determining if there was a low-grade inflammation, not 
detectable by visual inspection, which could explain the pain-like behavior. Analysis of 
histological sections from the mice 5 days after injection of antibodies showed little signs of 
cell infiltration, bone erosion or cartilage destruction. We then decided to analyze the gene 
expression in the ankle joints, to see if there was elevation of any factors associated with 
arthritis pathology or pain signaling, like Tnf, Cox2, and MMPs. None of the factors we 
analyzed were elevated 5 days after injection of antibodies. We also analyzed the activity of 
MMPs using MMPsense, which revealed no increased activity of the enzymes. These results 
suggest that other factors than those involved in innate inflammatory and bone remodeling 
drive anti-CII mAb induced mechanical hypersensitivity prior to onset of joint inflammation. 
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4.2.2 Pain-like behavior was apparent as early as two days after injection of 
antibodies 
To determine the temporal profile of the pain-like behavior, we examined the thresholds for 
response to mechanical stimulation every day during the 5 first days after injection of anti-CII 
antibodies (Fig. 13). By day 2 there was already a significant reduction in tactile thresholds 
compared to control mice. We decided to monitor mouse locomotion, which is a non-evoked 
measure that can indicate spontaneous pain in rodents, around that time point. The 
measurement takes place during the whole night, which is their active period. Antibody-
injected mice showed reduction in total movement, ambulatory movement, as well as in 
rearing. 
 
Figure 13. Anti-CII 
antibody-induced 
behavioral changes. 
Anti-CII cocktail was 
injected and mechanical 
sensitivity assessed (A), 
visual signs of 
inflammation expressed 
as arthritis score 0-60 
(B), and arthritis 
incidence (C). 
Locomotor activity was 
monitored during the 
third night (12 h) after 
injection (D).  
 
4.2.3 Antibody epitope recognition, but not pathogenicity, is important in 
early antibody induced pain-like behavior 
The cocktail of antibodies (M2139, CIIC1, UL1, and CIIC2) used to induce CAIA are 
directed against four conserved epitopes present on both human and mouse CII protein. It has 
been demonstrated that these antibodies are associated with varying degree of pathogenicity 
when injected alone. We wanted to test if this factor is linked to the ability to induce pain-like 
behavior, so we injected the antibodies separately. Interestingly, each antibody induced a 
similar degree of hypersensitivity, this was comparable to results following injection of the 
mixed cocktail. Isotype control antibodies did not induce any changes. Injection of only 
M2139 reduced locomotion in the mice, as well as causing long-term mechanical 
hypersensitivity at doses that did not induce joint inflammation for at least 21 days. 
The antibody ACC4 binds the citrullinated C1 epitope on CII but is not able to induce 
inflammation on its own, making it an interesting comparison to the previous anti-CII 
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antibodies. Surprisingly, the ACC4 induced similar mechanical hypersensitivity and 
reduction in locomotion as the antibodies binding to native CII. Taken together, this suggests 
that although epitope recognition is critical, antibody-induced pain-like behavior is not 
coupled to the pathogenicity of the antibodies. 
4.2.4 Complement activation or changes in cartilage structure does not 
contribute to early pain-like behavior. 
One of the primary effector functions for antibodies is activation of the complement cascade 
through the classical pathway. This leads to release of complement component 5a (C5a), 
which is able to directly activate nociceptors. We thought this could be a potential mechanism 
of induction of pain-like behavior. To test this, we used pharmacological inhibition of the C5 
receptor using a peptide antagonist and performed experiments using congenic mice deficient 
in the C5 protein. Neither of these experiments prevented changes in locomotion or 
mechanical hypersensitivity, thus not supporting a major role for complement activation in 
antibody-induced nociception. 
The anti-CII antibodies have been shown to destabilize the cartilage structure in vitro and 
cause an early loss of cartilage proteoglycans in vivo, demonstrating a direct effect on 
cartilage. To determine if induction of pain-like behavior is linked to these processes we used 
ACB mice with or without collagen typ IX (CIX-/-) deficiency. The ACB mouse is an IgG 
heavy chain knock-in mouse that spontaneously produce anti-CII antibodies that bind to the 
C1 epitope. Collagen type IX stabilizes the cartilage structure and absence of CIX leads to an 
increased cartilage porosity, enabling deeper penetration of the antibodies. The ACB and the 
ACB CIX-/- mice did not differ in tactile threshold baselines, and when injected with anti-CII 
antibodies, they both developed both evoked and spontaneous pain-like behavior to a similar 
degree. This indicates that stability and integrity of cartilage did not influence early pain-like 
behavior.  
The CIIF4 antibody binds CII but does not induce any changes in the cartilage structure and 
protects antibody-mediated cartilage damage both in vivo and in vitro. In fact, it prevents 
development of arthritis when injected together the anti-CII cocktail. Interestingly, the 
injection of CIIF4 antibody in mice produced robust mechanical hypersensitivity of the same 
degree as anti-CII mAbs. Taken together, these data further support our findings that change 
in cartilage structure and pathogenicity of the antibody are not critical factors for induction of 
antibody-mediated nociception. 
 
4.2.5 CII immune complex has a direct effect on cultured DRG neurons 
Based on the finding described above, we formulated the hypothesis that anti-CII antibodies 
may have a direct effect on peripheral neurons, through mechanisms that are uncoupled from 
the inflammatory process. In order to test this hypothesis, primary DRG neuronal cell cultures 
were prepared and stimulated with immune complex (IC) made from anti-CII antibodies and 
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the protein CII. The immune complex, but not anti-CII antibodies, CII alone, or isotype 
controls, induced release of the peptidergic neurotransmitter CGRP. Expression of CGRP is 
common in nociceptors innervating the joint and bone. 
In order to further investigate the potential role of CII-IC as a direct activator of nociceptive 
sensory afferents, we used two other functional assays commonly used for assessment of 
neuronal activity. We first investigated the effect of CII-IC on intracellular Ca2+ levels (Fig. 
14). Application of CII-IC caused a Ca2+ response in 22% of the neurons (responding to KCl). 
To simulate more physiological conditions, we also pre-incubated the cultures with isotype 
control antibodies before application of the IC, giving a similar response rate of 21%. 
Next we performed electrophysiological recordings in small diameter neurons, which are 
mostly C-type primary afferents and more likely to mediate nociceptive signals than the large 
diameter A-type afferents. We focused on a subpopulaton of small diameter nociceptive 
neurons that express TRPV1, and we used the TRPV1 agonist capsaicin for verification at the 
end of each experiment. Of the cells recorded, 48% gave inward current responses to 
capsaicin and of those, CII-IC evoked inward current in 42%.  
 
Figure 14. The effect of CII-IC on cultured DRG neurons. Representative traces are showing 
increased intracellular Ca2+ in response to CII-IC but not isotype control antibody IgG2b. 
 
4.2.6 FcγRs are present on sensory neurons 
Our data suggest a direct action of CII-IC on sensory neurons, thus implicating a role of 
receptors for IgG: FcγR. We started by analyzing gene expression data from DRG mRNA 
extracts, which revealed that all transcripts were present (Fcgr1, Fcgr2b, Fcgr3, and Fcgr4), 
with the highest expression of Fcgr2b and Fcgr3. This was confirmed with quantitative real 
time PCR, which preseted with a similar expression pattern. We also analyzed publically 
available gene expression data from human DRG samples, which showed mRNA of all 
FCGRs with the highest relative expression of FCGR2A and 2C. The presence of FcγR 
protein in mouse DRG was determined by proteomic analysis using high performance 
nanoLC-MS/MS. By doing so, we detected two unique peptides originating from FcγRIIb, 
along with two other non-unique peptides shared between FcγRIIb/III. Peptides from FcγRI 
or FcγRIV were not detected. To determine the cellular localization of FcγRIIb, single 
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molecular fluorescence in situ hybridization (smFISH) was used, showing that Fcgr2b 
transcripts were restricted to a subset of neurons in the DRG. Additionally, by using 
immunohistochemistry, FcγRIIb was located to neurons in the DRG, while FcγRI and 
FcγRIII were restriced to non-neuronal cells. Presence of FcγRIV was not detectable. Co-
localization studies showed that FcγRIIb is expressed in small and medium sized neurons, 
including TRPV1+, CGRP+, and non-peptidergic IB4+ neurons (Fig. 15). 
 
 
Figure 15. Presence of FcγRs in DRG. Relative expression of mRNA in mouse for Fcgr1-4 using 
microarray (A) and qPCR (B). Relative expression of mRNA in human DRG for FCGR1-3B using 
microarray (C). Representative result from smFISH for Fcgr2b (green) and DAPI (blue) in mouse 
DRG (D). Immunoreactivity for FcγRI (E), FcγRIIb (F), FcγRIII (G), and FcγRIV (H) in mouse 
DRG. 
 
4.2.7 Antibody – FcγR interaction is necessary for nociceptive effect in vivo 
In order to investigate if FcγR binding the Fc part of the antibody is required for nociceptive 
effects, we removed the Fc from the anti-CII antibodies and injected the remaining Fab-
fragments and measured mechanical sensitivity and locomotor activity. Mice injected with 
anti-CII mAb Fab did not develop any signs of evoked or spontaneous pain-like behavior and 
did not differ behaviorally from control mice injected with saline. Antibodies with an 
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endoglycosidase (EndoS) hydrolyzed glycan on the heavy chain (γ-chain) at asparagine 297 
have a diminished affinity for FcγR interaction. To test the functional importance for Fc 
mediated FcγR activation in antibody-induced nociception, EndoS treated anti-CII antibody 
was injected to a group of mice. EndoS-treated antibodies did not induce mechanical 
hypersensitivity or reduction in locomotor activity compared to control mice. Additionally, 
anti-CII mAbs were injected in mice that lack the common γ-chain, thus without functional 
FcγRI, FcγRIII, and FcγRIV, and compared with wild type. The FcRγ-/- mice were resistant 
to antibody-induced mechanical hypersensitivity. These results indicate that the binding of 
Fab to CII is not sufficient to activate nociceptors, that glycosylated Fc and presence of 
activating FcγRs are required. Hence the antibody-FcR interaction is necessary in vivo for 
antibody-induced pain-like behavior. 
To summarize, we propose a mechanism that is dependent on antibody interaction with 
FcγRs for induction of pain-like behavior. Anti-CII antibodies bind the cartilage in the joint, 
forming IC that can activate local FcγRs. The activation of FcγRs on local immune cells 
causes release of factors that prime sensory neurons in the joint area. These neurons can be 
directly activated by the ICs through the expression of FcγRIIb, present on both peptidergic 
and non-peptidergic neuronal populations. Disruption of the antibody – FcγR crosslinking 
inhibits the pain-like behavior. 
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5  DISCUSSION AND CONCLUDING REMARKS 
This thesis focuses on mechanisms of pain in autoimmunity and how antibodies interact with 
the sensory system. The nervous and immune systems have traditionally been regarded as 
two separate entities with separate functions and structures, and thus are studied separately. 
Information in the nervous system is relayed quickly by electrical signals through relatively 
static nerve fibers, while the immune system is inherently mobile and dispersed, depending 
on the movement of cells through tissues and into the circulation. Both systems are critical 
for an organism responding to the danger imposed on tissue homeostasis, and both are highly 
adapted to sense both internal and external environments. However, emerging evidence point 
towards extensive crosstalk between the two systems, acting in coordinated ways to promote 
an effective defense for the organism. The systems communicate through a common 
language of cell-surface receptors and released proteins and peptides. In fact, as a greater 
number of mediators that are common to the immune and nervous systems are discovered, 
terms such as “cytokine” and “neuropeptide” becomes misleading. 
Unfortunately, being a vital component for the health of organisms, neuro-immune crosstalk 
also contributies to disease states, including autoimmunity. A better understanding of the 
coordinated interaction of peripheral neurons with immune cells might advance therapeutic 
approaches, both in suppressing the immune system and the mechanisms contributing to 
chronic pain. 
In Paper I and II we investigated the effect of anti-citrulline immunity and found that ACPA 
induced osteoclast activity, causing bone erosion and pain-like behavior in mice (Fig. 16). It 
introduces a new perspective on the role of antibodies against citrullinated proteins, of which 
little is known. As with most research, the results lead to more questions than answers. A 
fundamental question that needs to be addressed is which epitope(s) are targeted and what 
mechanism triggers the CXCL1/IL-8 release? The CCP assays used for diagnosis use a 
generic synthetic peptide that is not present in vivo. Several citrullinated epitopes on proteins 
are targeted by ACPA, including CEP-1, vimentin, and fibrinogen, but most monoclonal 
antibodies studied so far show remarkable cross-reactivity (Amara et al., 2013). Additionally, 
the citrullination status of individuals changes during the disease course, inflammation in a 
joint is associated with increased citrullination (Romero et al., 2013), which is quite distinct 
from a naïve state. We show that citrullinated antigens are a vital part of osteoclast formation, 
and the antibodies bind those structures. It is possible that other cell systems also use 
citrullination during normal physiology, which could potentially be targeted by ACPA. Since 
we find that some monoclonal ACPA do not induce pain-like behavior, it is important to find 
which epitopes are involved to be able to predict anything about pain in patients, and 
potentially device serological tests based on this. 
 The ACPA we have used in these studies, both monoclonal and polyclonal pool, comes from 
diagnosed patients at the rheumatology clinic, i.e. persons that had autoantibodies for some 
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time. It would certainly be informative to harvest antibodies and cells from individuals 
longitudinally, to establish the nociceptive and erosive effects of ACPA during the maturation 
of the disease. Especially around the time when there is a rapid change in the anti-citrulline 
immunity: sharp increases in antibody levels and number of specificities, as well as epitope 
spreading (Sokolove et al., 2012). In practice, this would be hard to perform but would give 
interesting information about the time point when the autoantibodies switch from benign to 
symptomatic. 
With a more detailed knowledge about the effects of anti-citrulline immunity, the term 
ACPA-positive could be classified as a disease state or syndrome. This would warrant earlier 
clinical treatment and hopefully inhibit progression into RA. 
In Paper III we investigate the role of anti-CII antibodies in initiation of nociceptive 
signaling, and find that anti-CII in immune complex formation directly activate sensory 
neurons through FcγRs, likely causing pain-like behavior in mice (Fig. 16). The anti-CII 
antibodies are quite distinct in some ways from ACPA, in that the precise epitope binding is 
well characterized and the effect this has on the collagen protein. The similarity is the 
relevance to RA, since anti-CII antibodies are present in some RA patients, targeting the 
same conserved epitopes. Additionally, these antibodies are also able to induce pain-like 
behavior without signs of inflammation, indicating a more complex effect than just activating 
immune cells. 
After injection, the anti-CII antibodies rapidly bind cartilage in the joints (Nandakumar et al., 
2003). The ability of the anti-CII antibodies to disrupt the cartilage structure in combination 
with availability of soluble CII in the normal synovial fluid (Lohmander et al., 2003), 
provides opportunity to form soluble ICs that can activate local FcγRs, in particular on the 
sensory neurons innervating the synovial tissue and bone structures. The pain behavior is also 
dependent on activation on local FcγR-expressing cells, most likely resident macrophages or 
fibroblast-like synoviocytes, to release factors that activate the neurons. Since mice lacking 
activating FcγRs do not display pain-like behavior, they may be important in activating these 
local immune cells to recruit silent nociceptors (Schaible et al., 2009). However, this 
activation of local cells is not sufficient for a detectable inflammatory response. 
We show for the first time the presence of FcγRIIb on sensory neurons. Previous in vitro 
effects by ICs on cultured DRG neurons has been attributed to FcγRI (Andoh and Kuraishi, 
2004; Qu et al., 2011). In some cases this could be explained by species differences, but a 
more likely factor is the availability of specific tools. Often in these reports, the method for 
determining cellular localization is based on immunoreactivity, which can be deceptive. We 
use several method to establish confidence in receptor expression. The notion that FcγRIIb is 
able to mediate an activating effect on neurons is quite interesting, since it is classically 
thought of as an inhibitory receptor on immune cells, either inhibiting the activating receptors 
or mediating endocytosis (Nimmerjahn and Ravetch, 2006). Early reports of direct effects of 
ICs on motor neurons show internalization in addition to activation (Mohamed et al., 2002). 
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The intracellular mechanisms of antibody- FcγRIIb crosslinking is certainly important to 
further explore. 
 The interaction between sensory neurons and the immune system during autoimmunity may 
have consequences for the progression of the disease as well. Activated sensory neurons 
release neuropeptides from their peripheral terminal, and immune cells express receptors for 
almost all of these known peptides (Talbot et al., 2016). For example, the neuropeptide 
CGRP has complicated modulatory effects on immune cells, important in antimicrobial 
defense (Augustyniak et al., 2012). Innervation and neuronal activity has been shown to 
regulate inflammation, where denervation protects patients and rodents from development of 
arthritis (Courtright and Kuzell, 1965; Stangenberg et al., 2014). This suggests that the 
sensory neurons have a vital role in regulating the local environment in the joint and cellular 
activity. Additionally, many immune cells produce and secrete NGF, an important growth 
factor for neurons that can trigger nociceptive neurons and remodeling of peripheral 
innervation (McMahon et al., 2015; Shepherd et al., 2005). This can create a neuro-immune 
amplification loop, in which immune cells secrete cytokines that activate neurons, and 
neurons secrete peptides that activate immune cells. During chronic autoimmune disease, this 
creates a primed state so flares can easily be triggered, due to disproportionate responses of 
the immune cells and pain fibers (Talbot et al., 2016). Thus, for patients, targeting both the 
overactive immune system and sensory system could potentially lead to a complete resolution 
of symptoms. Here we provide evidence that autoantibodies can be an important part of that 
loop, and a possible target for intervention against chronic pain. 
 
 
 
 
 
 
 
 
 
 
Figure 16. Summary of proposed pain-inducing mechanisms. 1) ACPA binds citrullinated 
epitopes on osteoclasts, causing release of CXCL1/IL-8 that can activate and sensitize sensory 
neurons, through the receptor CXCR2. 2) Antibodies in IC-formation can directly activate sensory 
neurons through FcγRs, causing pain-like behavior.
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